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EPIDEMIOLOGY OF TYPE 1 DIABETES COMPLICATIONS IN  
 AFRICAN-AMERICANS 
Raynard E. Washington, DrPH 
University of Pittsburgh, 2012 
Unlike type 2 diabetes, where prevention is possible, type 1 diabetes is a lifelong incurable 
metabolic disorder. The annual incidence of type 1 diabetes continues to rise annually. Despite 
increased access to treatment and improved disease management, type 1 diabetes is associated 
with excess morbidity and early mortality. African-Americans with type 1 diabetes are at 
increased risk of premature mortality compared to Caucasians. This disparity is likely fueled by 
differences in the prevalence of complications; however, there is limited information available 
on the racial differences in type 1 diabetes complications in individuals of African descent (i.e. 
African-American, Afro-Caribbean). Using the data from the U.S. Virgin Islands Childhood 
Diabetes Registry, this dissertation provides contemporary insights on the incidence of childhood 
diabetes in African-American youth and for the first time evaluates type 1 diabetes mortality in 
African-Americans, in the U.S. Virgin Islands. In addition, this dissertation assesses racial 
differences in the prevalence of type 1 diabetes complications and risk factors using a national 
sample from the National Health and Nutrition Examination Survey. 
The incidence of type 1 and type 2 diabetes in youth in the U.S. Virgin Islands is rapidly 
increasing. The well-established pubertal increase in type 1 diabetes incidence appears to be 
missing in African-American boys. Individuals diagnosed at later ages (>14), have significantly 
higher risk of mortality compared to those diagnosed at earlier ages. Despite advances in 
diabetes care, there were no temporal improvements observed in mortality in the U.S. Virgin 
v 
 
Islands. African-Americans in the U.S. Virgin Islands had a similar type 1 diabetes mortality 
experience as African-Americans in Allegheny County, PA. African-Americans in the national 
sample had significantly higher rates of nephropathy and retinopathy. Race was associated with 
both complications, even after adjusting for clinical and demographic factors. 
The public health implications of this dissertation are considerable, as it provides insight 
on the burden of type 1 diabetes in the U.S. Virgin Islands and African-Americans in the U.S. 
These findings provide evidence to support additional services and potentially intensive diabetes 
management strategies for African-Americans with type 1 diabetes.  
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1.0  INTRODUCTION 
Type 1 diabetes is associated with considerable excess morbidity and early mortality. Despite 
significant advances in disease management and care, African-American youth have been shown 
to have poorer management of T1D, often confounded by poor socioeconomic conditions, which 
likely increases risk for complications. Research has demonstrated that African-Americans are at 
nearly 3-fold increased risk of mortality associated with T1D, compared to Caucasians. This is 
likely fueled by disparities in the morbidity of complications, however this difference remains 
unclear. While epidemiologic investigations have extensively described the natural history of 
T1D and complications in various populations, there is limited information available on the 
prevalence of complications and risk factors specifically in African-Americans, in comparison to 
other racial groups, particularly Caucasians. Existing prospective cohort studies have insufficient 
ethnic diversity to allow for racial comparisons. There is currently no information on the 
prevalence of T1D complications and risk factors in the U.S. Virgin Islands, a culturally unique 
and predominantly African-American population where the incidence of T1D seems to be 
increasing.   
As such, the objectives of this dissertation are to: 
1. Estimate the annual incidence of childhood diabetes in the U.S. Virgin Islands in 
recent years, including an analysis of contemporary trends, demographics and risk 
profiles. 
2 
 
2. Estimate mortality in an African-American cohort in the U.S. Virgin Islands and 
compare to a predominantly Caucasian cohort, using similar data collection methods. 
3. Compare the prevalence of T1D complications and risk factors in African-
Americans and Caucasians in the U.S. using data reported in the National Health and 
Nutrition Examination Survey.  
The outcomes of this dissertation will expand the current knowledge of diabetes complications in 
African-Americans and the U.S. Virgin Islands and create a foundation for understanding 
disparities in T1D-related health outcomes in the U.S. 
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2.0  BACKGROUND 
2.1 DIABETES MELLITUS 
Diabetes mellitus is a group of metabolic diseases marked by increased levels of blood glucose 
as a result of inadequate insulin production or defects in insulin activity and in many instances a 
combination of both. World Health Organization estimates that more than 220 million people 
worldwide have diabetes, with approximately 1.1 million diabetes-related deaths occurring 
annually.1 Centers for Disease Control and Prevention estimates that approximately, 23.6 million 
(7.8%) U.S. adults and children have diabetes, with over 5 million undiagnosed cases, and 
estimated 54 million having pre-diabetes.2 The prevalence of diabetes in the U.S. is expected to 
increase by nearly 42.4% by 2030.3 Diabetes is the currently the 6th leading cause of death in the 
U. S. with most deaths occurring as result of an acute or chronic complication of diabetes.4 
African-Americans are disproportionately affected by diabetes, predominantly due to increased 
prevalence of T2D in African-American adults.2, 5, 6, 7 Despite increased access to treatment and 
improved disease management, the major complications of diabetes persist as significant sources 
of morbidity and early mortality; thereby further fueling the increasing burden of the disease. 
The three major types of diabetes are Type 1(T1D), Type 2(T2D), and gestational.  
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Type 1 Diabetes 
T1D (formally known as insulin-dependent diabetes mellitus (IDDM)) is characterized by 
deficiencies in pancreatic β cell insulin production. Insulin is a peptide hormone usually secreted 
by pancreatic β cells in response to food uptake. The digestive system is responsible for the 
conversion of food to glucose, which eventually diffuses into the bloodstream. Insulin allows 
cells to properly uptake glucose from the bloodstream to be metabolized for energy or stored. 
When insufficient amounts of insulin are available, cells do not receive the necessary fuel to 
perform functions and glucose builds up in the blood stream, leading to high blood glucose 
levels, also known as hyperglycemia. In some instances, there is too much insulin available, most 
often due to administering higher insulin doses than necessary, resulting in low blood glucose 
levels, or hypoglycemia. The exact etiology of T1D remains unclear, but it is believed to be 
caused by a combination of autoimmune, genetic, and environmental factors, resulting in the 
immune system attacking pancreatic β cells and diminishing insulin production over time.8, 9, 10 
Long-term pancreatic β cell destruction eventually results in total insulin deficiency, requiring 
lifelong exogenous insulin administration. In addition to hyperglycemia, individuals with T1D 
typically present at onset with increased symptoms, such as thirst and polyuria, resulting from 
the excess glucose levels being excreted in the urine, and increased appetite, caused by glucose-
deprived cells sending signals to the brain to increase food intake.8 T1D is most often diagnosed 
at young ages, but can be diagnosed at any age, and accounts for approximately 5-10% of 
diabetes in the U.S.2 
Type 2 Diabetes 
T2D (formally known as non-insulin dependent diabetes mellitus (NIDDM)), the predominant 
and preventable type, accounts for 90-95% of diabetes in the U.S and is traditionally associated 
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with obesity, older age, family history of diabetes, physical inactivity, and certain ethnicities, 
including African-Americans and Hispanics.6, 7 With the growing obesity epidemic, prevalence 
of T2D continues to rise in all age groups and ethnicities, most notably children. T2D results 
from a combination of insulin deficiency, due to insufficient insulin production by pancreatic β 
cells, and insulin resistance, inadequate use of available insulin by cells.2, 7 At onset of T2D, the 
pancreas usually produces sufficient amounts of insulin, but due to increased insulin resistance, 
the body’s cells do not effectively use the available insulin, resulting in hyperglycemia. The 
pancreas produces more insulin to account for increased blood glucose and energy starved cells 
signal the process of hepatic glucose production further increasing blood glucose levels. The 
liver may also become insulin resistant, decreasing its uptake of blood glucose and sensitivity to 
restricting glucose production. Prolonged over working of pancreatic β cells leads to reduced 
function and insulin production, and may eventually lead to the need for insulin therapy. 
Gestational Diabetes 
Gestational diabetes accounts for <1% of cases in the U.S. and results from glucose intolerance 
during pregnancy, and often subdues during the post-partum period, often recurring later in life.2 
2.2 EPIDEMIOLOGY OF TYPE 1 DIABETES 
The global incidence of T1D continues to rise approximately 3% annually.11, 12 The WHO 
DiaMond Study is an international study of childhood onset T1D.11 This study fostered the 
development of a large number (approximately 150) of population-based T1D registries across 
the world. Compiled data from these registries indicates high variation in the incidence of T1D in 
the respective countries, ranging from <1 per 100,000 per year in populations from South 
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America and China to the highest of 40.9 per 100,000 per year in Finland. Other studies 
assessing the incidence of T1D in various countries world-wide have also shown similar 
variations in T1D incidence.13, 14 
United States 
The prevalence of T1D in the U.S. varies by race, ethnicity, age, and geographical location. The 
SEARCH for Diabetes in Youth Study, an ongoing effort to monitor the incidence of both T1D 
and T2D among U.S. youth, estimates the annual incidence of T1D to be 19.0 per 100,000.15 The 
highest incidence of T1D occurs in non-Hispanic whites and those in the 10-14 age group. 
African-Americans maintained a lower incidence of T1D at 15.7 per 100,000 for all age groups, 
compared to 23.6 per 100,000 in Caucasians, for the 2001-2003 time period.16 However, socio-
demographic and clinical profiles for African-American youth were significantly worse than 
Caucasians, which may suggest an increased likelihood for poorer health outcomes. More than 
one-third of African-American youth with T1D had a household annual income less than 
$25,000, compared to less than 10% of Caucasians. Approximately 53.4 % of African-American 
youth lived in 1-parent households. More African-American youth (27.9%) seemed to present 
with diabetic ketoacidosis at onset, compared to Caucasians (21.8%). Consistent with previous 
studies of risk profiles in youth with diabetes, African-American youth with T1D had 
significantly worse glycemic control compared to Caucasians.(Table 1)17 Glycemic control was 
associated with age in both races, with more older youth having poor glycemic control. In 
addition to poorer glycemic control African-American youth were more likely to be overweight, 
have increased LDL cholesterol, high blood pressure, high degree of depression-related 
symptoms, and meet fewer dietary recommendations, compared to Caucasians. 
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Table 1: SEARCH Study - Percent of Youth with T1D HbA1C ≥ 9.5% by Race and Age Group 
 0-9 Years (%) 10-14 Years (%) ≥15 Years (%) 
African-American 24.5 40.2 46.0 
Non-Hispanic White 4.7 11.2 21.5 
 
U.S. Virgin Islands 
The U.S. Virgin Islands, a U.S. territory, consist of four inhabited islands (St. Croix, St. Thomas, 
St. John, and Water Island) with a total population of 108,612 individuals. Approximately 76.1% 
of the population are non-Hispanic blacks, and 13.1% are non-Hispanic whites, with the 
remaining being a combination of Hispanic and Asian ethnic groups.18 Consistent with 
continental U.S., diabetes persists as a major source of morbidity and mortality for the U.S. 
Virgin Islands. Approximately 9.7% of the territories population has been diagnosed with 
diabetes.19 Diabetes is the 5th leading cause of death in the territory.20 A childhood diabetes 
registry was established in the U.S. Virgin Islands as a part of the WHO DiaMond Study to 
further evaluate the epidemiology of T1D in the territory. The registry is composed of cases from 
all hospitals and health clinics in the three main islands (St. Croix, St. Thomas, and St. John). 
Cases are defined as any individual diagnosed with T1D less than 19 years old living in the 
territory at the time of diagnosis.21 Initial studies were conducted on individuals diagnosed 
between January 1979 and December 1988. This time period reflected an annual incidence of 7.5 
per 100,000, with rates being significantly higher in non-Hispanic whites compared to non-
Hispanic blacks and Hispanics.22 The incidence of T1D in the U.S. Virgin Islands is higher than 
other Caribbean islands with similar ethnic compositions and distributions.23 Recent data from 
the registry suggests an increasing incidence of T1D in the territory; however it has not been 
formally reported. 
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2.3 TYPE 1 DIABETES COMPLICATIONS 
T1D is a lifelong metabolic disorder and chronic hypo- and hyperglycemia often experienced by 
patients can lead to many complications, including death. The major complications most 
frequently associated with T1D, and T2D, can be grouped as microvascular, including 
neuropathies, nephropathy, and retinopathy, or macrovascular, including atherosclerotic 
conditions such as coronary artery disease, peripheral vascular disease, and cerebrovascular 
disease. The presence or combination of these conditions often leads to the ultimate 
complication, premature death. Studies have shown clear racial differences in mortality 
associated with T1D; however, there are limited data comparing racial differences in the 
prevalence of T1D complications and risk factors.24, 25, 26, 27, 28, 29 
Overview of Major Complications 
T1D can cause various types of nerve damage leading to diabetic neuropathy. There are two 
major classifications of neuropathies: peripheral, resulting from nerve damage in the arms and 
legs, typically beginning in the hands and feet, and autonomic, resulting from damage to the 
nerves that regulate vital functions, including the smooth muscles of the heart and other vital 
organs.30 
Distal Symmetric Polyneuropathy (DSP), a peripheral neuropathy occurring most often in 
the feet and legs, is the most common type found in patients with T1D.31 The clinical symptoms 
of DSP typically begin with numbness, pain, and/or paresthesias in the feet and legs, which may 
eventually lead to ulcers and in severe cases, require limb amputation due to infection.  DSP is 
usually diagnosed by signs of heightened sensory loss, motor loss, including weakness and 
atrophy, and depressed tendon reflexes.30 
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Cardiac Autonomic Neuropathy (CAN) is also common in patients with T1D. Previous 
studies have shown that CAN is significantly associated with increased risk of mortality in 
patients with T1D.32, 33 CAN damages the autonomic nerve fibers innervating the heart and blood 
vessels. CAN causes abnormalities in heart rate control and hemodynamics, resulting in the 
inability of patients to regulate cardiac output or redirect blood flow. This inadequate regulation 
of cardiac output often leads to reduced heart rate variation, resting tachycardia, exercise 
intolerance, and orthostatic hypertension. 31 CAN is usually detected clinically by exercise stress 
test, blood pressure response to standing, and heart rate variability during deep breathing.31 
The complete pathogenesis of diabetic neuropathy remains unclear, though chronic 
hyperglycemia is suspected to play a primary role in its development.34 The Diabetes Control 
and Complications Trial (DCCT) provided further evidence for this causal relationship by 
demonstrating a significant decrease in the development and progression of neuropathy by 
improving glycemic control through intensive therapy.35 This reduction of risk due to improved 
glycemic control was maintained in subsequent follow-up of the DCCT.36 The complexity and 
varying methodologies of diagnosis has limited the inclusion of neuropathy in many early T1D 
complication studies and racial differences have not previously been investigated.37, 38 
Diabetic retinopathy is the most common eye complication in diabetes and the leading 
cause of new cases of blindness among adults in the U.S.39 Diabetic retinopathy is caused by 
damage to the blood vessels in the eye from chronic hyperglycemia. Diabetic retinopathy 
clinically presents in progressive stages. The first is commonly referred to as mild to severe non-
proliferative diabetic retinopathy (NPDR). At the early stages of NPDR, microaneurysms, small 
areas of balloon-like swelling in the retina’s small blood vessels, occur. As NPRD progresses, 
examination of the retina may also reveal small dot and blot hemorrhages and blockage of more 
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blood vessels in the retina. The more advanced form of diabetic retinopathy is referred to as 
proliferative diabetic retinopathy (PDR), which involves increased damage to circulation in the 
retina. In response, neovascularization occurs, resulting in the development of weak and fragile 
blood vessels in the retina and possibly the vitreous, the fluid space in the back of the eye. These 
fragile blood vessels tend to hemorrhage leading to leakage of blood in the eye causing clouded 
vision. Further progression of PDR can ultimately lead to blindness.40 
Diabetic nephropathy is a progressive kidney disease caused by damage to the capillaries 
of the kidneys, likely due to chronic hyperglycemia and genetic susceptibility.41, 42, 43 This 
process begins with thickening of the kidney glomerulus, the blood vessels in the kidney 
responsible for filtering blood and forming urine. Further thickening of the glomerulus results in 
increased amounts of serum protein (albumin) in urine, known as microalbuminuria. 
Microalbuminuria is the first stage of diabetic nephropathy and is detectable by urine analysis for 
an increased albumin excretion rate. Routine urine analysis is essential for patients with diabetes 
as microalbuminuria is typically asymptomatic and early detection is critical to delay and 
prevention of further progression. As kidney damage worsens, the concentration of protein in 
urine increases eventually progressing to overt nephropathy, clinically diagnosed by “dipstick” 
positive urinalysis, and eventually End Stage Renal Disease (ESRD).  
Cardiovascular disease is a group of macrovascular complications caused predominantly 
by the development of atherosclerosis in blood vessels throughout the body. Atherosclerosis is a 
slow progressive process in which the artery walls thicken due to build-up of fatty materials 
leading to the formation of plaques. Plaques are formed in large part due to the accumulation of 
cholesterol resulting from the formation of foam cells, following low-density lipoproteins 
penetration into the arterial wall. Plaques can make the artery narrow and less flexible, restricting 
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blood flow, leading to angina and more significantly they may rupture, leading to the formation 
of a blood clot which completely blocks blood flow. Pieces of plaque can also break off and 
move through the affected artery to smaller blood vessels, blocking them and causing tissue 
damage or death. There are three major types of CVD most often associated with T1D: CAD, 
peripheral vascular disease (PVD), and cerebrovascular disease. 
CAD is the development of atherosclerosis in the blood vessels supplying oxygenated 
blood to the heart. The most common symptom of early CAD is chest pain, referred to as angina 
pectoris. Cardiac ischemia, or reduction of blood flow to the heart muscle, may also be detected 
by electrocardiogram (ECG), either at rest or during exercise (a stress test); however, it can often 
be undetected. A major complication of CAD is the rupturing of a plaque, leading to myocardial 
infarction, which is commonly known as a heart attack, and is often fatal. Other coronary 
complications of atherosclerosis include arrhythmias, abnormal speed and rhythms of the 
heartbeat, ischemic cardiomyopathy, deterioration of heart muscle, or heart failure, caused by 
prolonged weakening of heart muscle from oxygen-deprivation. Confirmed myocardial 
infarction, angioplasty (surgical procedure to increase blood flow in obstructed blood vessels), 
and CAD death, are classified as “hard CAD”, while early stages of disease (i.e. angina and 
electrocardiogram (ECG) changes), which are more difficult to define, are considered “soft 
CAD”. 
Peripheral vascular disease (PVD) is the presence of atherosclerosis in areas outside of 
the heart and brain. Lower-extremity arterial disease (LEAD) is a common manifestation of PVD 
in T1D. LEAD is obstruction of circulation in the blood vessels in the legs and feet. LEAD 
typically begins with symptoms of claudication during physical activity, including pain, 
weakness, fatigue and discomfort in the legs and feet; which subdue after rest. Overtime, these 
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symptoms will appear while at rest, indicating further progression of occlusion of blood flow in 
the lower extremities. LEAD can cause foot ulcers and in severe cases leads to gangrene and 
limb amputation. 
Cerebrovascular disease is caused by atherosclerosis in the blood vessels in the brain. The 
major complication of cerebrovascular disease is stroke, damage to brain tissue resulting from 
occlusion of blood flow to the brain due to atherosclerosis (ischemic) or rupturing of weak blood 
vessels (hemorrhagic). Ischemic stroke may occur from a blood clot forming at the site of 
atherosclerosis in a blood vessel supplying blood to the brain, known as thrombotic stroke. 
Ischemic stroke may also be caused by a blood clot that formed some place other than in the 
brain, for example the heart, that traveled to the small blood vessels of the brain leading to an 
embolic stroke. Unlike ischemic stroke, hemorrhagic stroke results from a weak blood vessel 
bursting and leaking blood into the brain. Blood vessel weakening is typically caused by blood 
vessel malformations or brain aneurysms (ballooning of a blood vessel in the brain).  
2.4 EPIDEMIOLOGY OF TYPE 1 DIABETES COMPLICATIONS 
 
Several key studies have been integral in establishing current knowledge of the epidemiology of 
T1D complications in both Caucasian and African-American populations; these include: the 
Epidemiology of Diabetes Complications Study and the New Jersey 725 Study.  
Epidemiology of Diabetes Complications Study 
The Epidemiology of Diabetes Complications Study (EDC) was initiated in 1985 as a 10-year 
prospective follow-up of a cohort of patients with Type 1 Diabetes diagnosed in childhood.44, 45 
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After 23 years of follow-up the EDC Study continues to provide an array of data concerning the 
prevalence, incidence, and inter-relationships of T1D complications and risk factors. Participants 
for the EDC Study were originally recruited from Children’s Hospital in Pittsburgh, PA. Eligible 
participants were diagnosed with T1D before age 17 years during 1950-1980. A total of 658 
individuals met the established criteria and were examined at baseline between 1986- 1988 to 
assess complication and risk factor status, and another 130 completed only surveys. 
New Jersey 725 Study 
The New Jersey 725 Study is the first large cohort study specifically investigating epidemiology 
of T1D complications in African-Americans. The study recruited 725 African-American 
participants from hospitals reporting to the New Jersey State Department of Health Diabetes 
Registry. The registry receives reports from 116 hospitals statewide, but IRB approval for 
medical chart review was only granted for 31 of the 116 hospitals. Eligible individuals were 
diagnosed with T1D before age of 30 between 1982 and 1996. The baseline examines were 
conducted between 1997 and 1999. The initial primary objective of the study was to assess the 
prevalence and risk factors for diabetic retinopathy in African-American patients with T1D, but 
subsequent follow-up included other major complications of T1D.46 
Neuropathy 
Diabetic neuropathy occurs in approximately 50% of patients with T1D by 20 years duration.31  
More than two-thirds of the EDC cohort had clinically detectable DSP by 30 years diabetes 
duration at baseline.31 The cumulative incidence of confirmed DSP in the EDC Study cohort at 
25 years diabetes duration was 20.8% in the 1970-74 diagnosis cohort compared to 33.6% 1965-
69 diagnosis cohort, indicating a reduction of DSP morbidity in the later cohort.47 Diabetes 
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duration, glycemic control, smoking, height and hypertension were significant risk factors for 
DSP. 
The prevalence of symptomatic CAN in EDC study cohort was nearly 39% at 25-years 
duration.32 Subsequent follow-up in the EDC study reported and incidence-density of 5.9 cases of 
CAN/100person-years. Age, glycemic control, and nephropathy were significant predictors of 
CAN.34 The prevalence and risk factors for neuropathy have not been reported in the NJ 725 
Cohort. 
Retinopathy 
In a national sample, diabetic retinopathy was more prevalent among men and non-Hispanic 
blacks. In addition, minorities appear to be more vulnerable to vision loss as a result of diabetic 
retinopathy.39 The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) showed 
that patients diagnosed early with diabetes (before age 30, likely T1D)  were at increased risk of 
developing diabetic retinopathy illustrated by a higher prevalence, 4-year incidence and 
proportion progressing to PDR, compared to patients diagnosed later in life (after age 30, likely 
T2D).40 
In the EDC Study, at 20 years duration, nearly 100% of EDC study participants had 
developed diabetic retinopathy. PDR was prevalent in more than 67% of cases by 30 years 
duration at baseline.45 The major risk factors for retinopathy were hypertension, glycemic 
control, and nephropathy.48 
At baseline, approximately 63.9% of the participants in the NJ 725 had some degree of 
diabetic retinopathy, with an average duration of 12.2 years, diagnosed by stereo fundus 
photography. Nearly 100% and 59.7% of those age 40 years and older had any diabetic 
retinopathy and PDR, respectively. In addition to diabetes duration and glycemic control; age, 
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hypertension, and proteinuria were significant risk factors for any diabetic retinopathy.46 At six 
years follow-up over 56% of the individuals at risk progressed to a more severe form of diabetic 
retinopathy. Consistent with previous findings poor glycemic control, diabetes duration, and 
hypertension were significant predictors of progression of diabetic retinopathy. Renal disease 
and age were explicitly predictive of progression to PDR.48 
Arfken et al conducted a prospective cohort study evaluating the comparable risk of 
developing PDR specifically in patients with T1D. African-Americans (n=97) had a nearly 2-
fold increased risk of developing PDR compared to Caucasians (n=215). At baseline, the 
African-Americans had poorer risk profiles than the Caucasians, including poorer glycemic 
control, higher systolic blood pressure and higher serum creatinine levels. The African-American 
subjects were older (mean age = 27 ± 15) compared to the Caucasian subjects (mean age = 19 ± 
11). However, there was no significant difference in the mean duration for African Americans 
(9.2 ± 7.0) compared to Caucasians (8.0 ± 6.4). After controlling for these risk factors, race did 
not significantly predict development of PDR. Consistent with previous studies, other significant 
risk factors were age, diabetes duration, and glycemic control.49 This is one of the few studies 
investigating racial differences in T1D complications exclusively in a cohort of T1D patients. 
Nephropathy 
Diabetic nephropathy is the leading cause of ESRD in the U.S., causing an estimated 28,000 new 
cases of ESRD per year. Despite the lower prevalence of T1D, nearly 50% of all diabetes-related 
ESRD occur in patients with T1D.50 Approximately 29% of patients with T1D develop 
microalbuminuria within the first 20 years of having diabetes.51 The prevalence of any 
proteinuria at 30-years duration in the EDC cohort was 84% in males and 59% in females at 
baseline, suggesting a significant gender difference in nephropathy. This difference was also 
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noted in the prevalence of overt nephropathy.37 In comparison, microalbuminuria was prevalent 
in 77.5% of those with at least 25-years duration in the NJ 725 Study.52 Consistent with findings 
in the EDC Study, at baseline, males were more than twice as likely to have microalbuminuria 
compared to females.53 Several studies, including EDC Study and NJ 725 Study, have shown that 
the major predictors of nephropathy are diabetes duration, glycemic control and the presence of 
hypertension.52, 53, 54Abnormal lipid profiles were also significant risk factors in the EDC 
Study.54 Subsequent follow-up in the NJ 725 Study also indicated depression as a risk factor for 
any diabetic nephropathy52; however, this association remains unclear and has not been 
duplicated. 
African-Americans with T1D appear to be at increased risk for developing diabetic 
nephropathy, though this risk has not been clearly quantified. Few population-based studies have 
shown an increased risk of ESRD for African-Americans with diabetes, both T1 and T2, 
compared to Caucasians.55, 56, 57 Cowie et al found a 2.6-fold higher incidence of ESRD in 
African-Americans compared to Caucasians after adjusting for the higher prevalence of diabetes 
among African-Americans. The study included patients with T1D and T2D; interestingly most 
African-Americans with ESRD had T2D, while most Caucasians with ESRD had T1D.57 
Numerous studies have shown overt nephropathy to be a major risk factor for coronary artery 
disease (CAD) and mortality in patients with T1D.58, 59 The precise mechanism mediating the 
association with CAD is not clear, but likely involves increased blood pressure, insulin 
resistance, and abnormal lipid profiles associated with diabetic nephropathy. 
Coronary Artery Disease 
CAD is the leading cause of death and diabetes-related deaths in the U.S. 4 Young adults with 
T1D have an estimated 10-fold increased risk of developing CAD compared to the general 
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population.59 At 25-years duration, 8% of EDC Study participants developed CAD.27, 60, 61At 6-
years follow-up, 15.9% of the NJ 725 study participants had some CAD, at 25-years duration.62  
Unlike the previously discussed microvascular complications, the role of hyperglycemia is not 
well defined in CAD. Lehto et al reported that poor glycemic control was a significant predictor 
of CAD in the late 1990’s.62 In contrast, larger studies have shown weak or no association 
between glycemic control and CAD.60, 63, 64 The EDC and other cohorts suggest that renal disease 
has a major impact on CAD outcomes. Interestingly, though neither baseline nor cumulative 
glycemic control were predictors in EDC, a follow-up analysis showed that change in glycemic 
control over time was a powerful predictor of CAD.61 The relationship between glycemia and 
CAD remains unclear, but it is possible that glycemic control may be a more significant predictor 
of CAD in the absence of renal disease, which would be consistent with Lehto et al  and the 
DCCT, which showed that improved glycemic control for six years had a profound protection 
against 20 year CAD risk, as unlike the EDC Study, in DCCT/EDIC, renal disease was rare.  
Peripheral Vascular Disease 
LEAD is a major cause of disability and morbidity in patients with T1D. Hospital discharge data 
indicate that 45% of all amputations in the U.S. are performed on patients with diabetes, and 
patients with diabetes are 15 times higher risk of amputation than patients without diabetes.65 
This includes amputations due to peripheral vascular disease in the extremities and those 
resulting from inadequate care of foot wounds and ulcerations. In the general, population 
African-Americans are at increased risk of LEAD.66 The WESDR and WHO DiaMond studies 
both reported increased mortality in T1D patients with amputations.67, 68 Previous studies have 
shown African-Americans and people of African-descent to be at increased risk of diabetes-
18 
 
related lower extremity amputation.69, 70 These studies were conducted in general diabetic 
populations and T1D specific analysis was not performed.  
At baseline in the EDC Study, 27% of those with greater than 25 years duration had 
PVD. Major predictors of LEAD were diabetes duration, low-density lipoprotein-cholesterol, 
heart rate, estimated glucose disposal rate, nephropathy, retinopathy, glycemic control, and low 
ankle brachial index (ABI).71 
Approximately 19% of the patients seen at the six-year follow-up in the NJ 725 study 
developed LEAD at 22-years duration. The overall prevalence in the cohort was 10.7 per 10,000. 
Similar to the EDC, the major risk factors for LEAD in this cohort were diabetes duration, 
hypertension, retinopathy, and presence/history of foot ulcers.72 In contrast to the EDC Study, 
however, males (16.7%) were at increased risk for developing LEAD, compared to females 
(10.2%) at 22-years duration, in the NJ 725 cohort. LEAD was defined as present if the patient 
had a limb amputation, angioplasty for poor circulation in the lower limbs, absence of one or 
more major arterial pulses in the lower limbs, or physician diagnosis, in the NJ 725 Study. In 
contrast, ABI, history of claudication as determined by the ROSE questionnaire and self-report 
of amputation or ischemia were used in the EDC Study. 
Cerebrovascular Disease 
Individuals with T1D have increased risk of stroke.73 Due to sample size restrictions, few studies 
have evaluated the magnitude of this risk. A study in the U.K. Diabetes Cohort, a cohort of all 
T1D patients, revealed that men of all ages had 3-fold increased risk of death from stroke, and 
women of all ages over 4-fold increased risk of death from stroke, compared to the general 
population.73 Other studies have reported up to a 6-fold increased risk of ischemic stroke in 
women with T1D.74 
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Over 18 years of follow-up, 4.4% of EDC Study participants had incident 
cerebrovascular events. In comparison, at six-year follow-up, 9.3% of the NJ 725 Study 
participants had incident cerebrovascular events. At 30-years duration, the cumulative incidence 
of stroke in the EDC cohort was 3.5%. At 23-years duration, the cumulative incidence of stroke 
in NJ 725 was 5.1%. Major predictors of stroke in the EDC were diabetes duration, non-HDLc, 
systolic blood pressure, and microalbuminuria. Roy et al did not report risk factors explicitly 
associated with stroke.62 
Mortality 
Premature death is the ultimate complication of T1D. Development of new and effective insulin 
therapies and management plans has greatly improved survival rates; however, patients with 
T1D are still at increased risk of death compared to the general population.26, 27, 29 The Diabetes 
Epidemiology Research International (DERI) Study has pioneered investigating mortality 
associated with T1D in population-based cohorts worldwide. DERI Study began as an effort to 
establish T1D registries in select countries, eventually merging with the previously described 
WHO DiaMond Study. Recent follow-up studies in DERI have focused primarily on T1D 
mortality in Allegheny County, PA, Finland, Israel, and Japan.75 These studies showed increased 
T1D mortality in the U.S. (represented by Allegheny County, PA cohort) compared to the other 
countries. A recent report from the Allegheny County, PA T1D Registry Cohort, initially 
affiliated with DERI, indicated that over 85% of deaths in the cohort were diabetes-related.29 The 
study also reported cause-specific mortality trends which showed that with increased diabetes 
duration the major causes of death shift from predominantly acute complications with in the first 
10 years of diabetes, to predominantly chronic complications in the later years (>20 years). 
Another major finding of this study was that African-Americans had nearly 3-fold increased risk 
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of death, compared to Caucasians. This disparity has been noted in previous studies in this cohort 
and others, as shown in Table 1.29 
Table 2: Mortality Rates (per 100,000 person-years (95% C.I.)) in T1D Cohorts by Race 
 Caucasians African-Americans 
Allegheny County Registry (1996) 380 (240 , 480) 910 (340, 1480) 
Allegheny County Registry (2001) 571 (478, 672) 1,388 (895, 2012) 
Allegheny County Registry (2005) 492.1 (412.1, 572.9) 1318.4 (1168, 1468.8) 
New Jersey 725 Cohort (2006) --- 2725.6 (1987.1, 3464.1) 
Chicago T1D Registry(2007) 48.2 (5.8, 174) 447.8 (283.9, 671.7) 
Allegheny County Registry (2010) 742.2 (648.1, 836.3) 1851.3 (1277.6, 2425.1) 
 
In 1996, Tull et al reported 2-fold excess mortality in African-Americans compared to 
Caucasians in the Allegheny County, PA Registry cohort, with females being at increased risk 
compared to males in African-Americans while no gender differences were present in 
Caucasians. This same study showed that African-American deaths were more likely (40%) due 
to acute complications compared to Caucasians (23%).24 A later follow-up of the same cohort by 
Nishimura et al showed overall improvements in survival for the individuals with shorter 
duration of diabetes, but the racial disparity persisted with African-Americans having 3-fold 
increased risk of mortality compared to Caucasians. There were no significant gender differences 
reported in this follow-up.26 A subsequent study in the Allegheny County, PA Registry cohort in 
combination with the Children’s Hospital of Pittsburgh Registry cohort supported previous 
findings, showing that African-Americans were at nearly 3-fold increased risk of mortality. In 
addition, this study confirmed earlier findings that African-Americans were at increased risk of 
death from acute complications compared Caucasians (Hazard Ratio = 4.9 (95% C.I. 2.0, 
11.6)).27 
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Studies evaluating racial differences in T1D mortality currently provide the strongest 
evidence of disproportionate T1D health outcomes in African-Americans. Other studies have 
shown similar results to those seen in the Allegheny County registries. Lipton et al reported that 
African-Americans were at nearly 9-fold increased risk for early mortality (<25 years of age) 
from acute complications in the Chicago T1D registry.25 There were no significant racial 
differences shown in overall mortality in a later study, but the analysis was limited by a small 
sample of non-Hispanic whites.28 
The 3-year crude mortality rate for the NJ 725 cohort was 8.6% [95%CI (6.6, 10.6)]. 
There were no significant gender differences in survival rates. Age, diabetes duration, 
nephropathy, presence of other major complications and heavy alcohol consumption were 
significant independent predictors of mortality in this cohort.76 Results from the EDC also 
indicated age, diabetes duration, and presence of other major complications as independent risk 
factors for mortality, but not alcohol consumption. 
In addition to premature death due to acute and chronic complications, a separate 
category of deaths exists in T1D, often referred to as “dead in bed syndrome”. Dead in bed 
syndrome was first reported in 1991, occurring in 22 young, apparently healthy T1D patients 
who were found dead in their beds.77 The typical characteristics of dead in bed syndrome are 
death during sleep, with no evidence of terminal struggle, sweating, or obvious cause of death.77, 
78, 79 Early researchers suggested that dead in bed syndrome was the result of nocturnal 
hypoglycemia, while contemporary hypotheses focus largely on some dysfunction in the 
autonomic system, specifically reduced parasympathetic activity; however the exact etiology 
remains unclear.77, 80, 81 Some evidence suggested that use of human insulin may be associated 
with reduction of typical hypoglycemic symptoms (sweating, dizziness, tremors, extreme 
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hunger/thirst); which may play a role in dead in bed syndrome.82 Recent studies reported that 
approximately 5-6% of all T1D deaths result from dead in bed syndrome.83  
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Table 3: Summary of Current T1D Complications Knowledge by Racial Group 
COMPLICATION  AFRICAN-AMERICAN CAUCASIAN 
NEUROPATHY   
Distal Symmetric 
Polyneuropathy 
 There is currently no data on the prevalence or risk 
factors of DSP in AAs with T1D 
 
EDC Study Cohort† (1990) 
 At baseline, more than two-thirds had clinically 
detectable DSP by 30 years duration.45 
 Risk Factors for DSP: Diabetes duration, glycemic 
control, smoking, height and hypertension.44 
Cardiac Autonomic Neuropathy  There is currently no data on the prevalence or risk 
factors of CAN in AAs with T1D 
EDC Study Cohort† (1990) 
 The prevalence of symptomatic CAN was 39% at 25-
years duration.32 
 Risk Factors for CAN: Age, glycemic control, and 
nephropathy.32 
RETINOPATHY   
 Arfken et al (1998) 
 17.5% of African-Americans progressed to proliferative 
retinopathy from baseline at 7 years follow-up.49 
NJ 725 Study Cohort (2000) 
 At baseline, approximately 63.9% had some diabetic 
retinopathy and 18.9% had proliferative retinopathy; with a 
mean duration of 12.2 years (±9.4).46 
 93% of cohort >45 years old had some diabetic 
retinopathy.46 
 At the 6-year exam, 72.3% of patients at risk, developed 
diabetic retinopathy.48 
 Risk Factors for Any and Proliferative Diabetic 
Retinopathy: Diabetes duration, glycemic control, age, 
hypertension, and nephropathy.46,48 
EDC Study Cohort† (1990) 
 At 20 years duration, nearly 100% developed some 
diabetic retinopathy.45 
 At 30 years duration, nearly 67% developed proliferative 
retinopathy.45 
 Risk Factors for retinopathy: hypertension, glycemic 
control, and nephropathy.44 
Arfken et al (1998) 
 10.2% of Caucasians progressed to proliferative 
retinopathy from baseline at 7years follow-up.49 
 
NEPHROPATHY   
 Cowie et al (1989) 
 Incidence of diabetic end-stage renal disease was 2.6-fold 
higher among AAs compared to Caucasians.55 
NJ 725 Study Cohort (2002) 
 At baseline, 84.6% of males and 45.5% of females had 
any proteinuria at 25 years duration.46 
 Risk factors for any proteinuria: diabetes duration, 
glycemic control, hypertension, depression.52 
EDC Study Cohort† (1990) 
 At baseline, 84% of males and 59% of females had any 
proteinuria at 30 years duration.45 
 Risk factors for any proteinuria: diabetes duration, 
glycemic control, hypertension, abnormal lipids53 
 
CORONARY ARTERY DISEASE   
Any CAD NJ 725 Study Cohort (2007) 
 At 6-years follow-up, 15.9% had clinically detectable or 
diagnosed CAD at 25-years duration.62 
EDC Study Cohort† (1990) 
 At baseline, approximately 8.0% had clinically detectable 
or diagnosed CAD at 25-years duration.45 
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 Risk factors for CAD: age, BMI, hypertension, 
nephropathy, retinopathy, and depression.62 
 Risk factors for CAD: age, diabetes duration, 
hypertension, BMI, total cholesterol.44 
CEREBROVASCULAR DISEASE   
Stroke NJ 725 Study Cohort (2007) 
 At 6-years follow-up, 9.3% of the NJ 725 Study 
participants had incident cerebrovascular events. 62 
 Approximately 5.4% reported a stroke at 23-30 years 
duration.62 
 Did not report significant risk factors for stroke in cohort. 
 
EDC Study Cohort† (1990) 
 At 18 years of follow-up, 4.4% of EDC Study 
participants had incident cerebrovascular events 
 At 30-years duration, the cumulative incidence was 3.5% 
 Risk Factors for Stroke: diabetes duration, non-HDLc, 
systolic blood pressure, and microalbuminuria 
PERIPHERAL VASCULAR 
DISEASE 
  
Lower Extremity Arterial 
Disease 
NJ 725 Study Cohort (2008) 
 At 6-years follow-up, 18.7% of those with greater than 
25-years duration developed LEAD.72 
 Risk Factors for LEAD: diabetes duration, hypertension, 
retinopathy, and presence/history of foot ulcers, male 
gender.72 
EDC Study Cohort† (1990) 
 At baseline, 27% of those with greater than 25-years 
duration had LEAD.45 
 Risk factors for LEAD: diabetes duration, LDL 
Cholesterol, heart rate, estimated glucose disposal rate, 
nephropathy, retinopathy, glycemic control, and ABI.44 
MORTALITY   
 Chicago T1D Registry (1999)25 
 Annual case-fatality rate was 451.3/100,000 for African-
Americans. 
 Most (91.4%) of the AA deaths resulted from diabetes-
related causes. 
Allegheny County Registry (2001)26 
 Crude Mortality rate was 1,388/100,000 person-years for 
African-Americans. 
 Standardized Mortality Rate was 645/100,000 person-
years for African-Americans. 
Allegheny County Registry (2005)27 
 Crude Mortality rate was 593.2/100,000 person-years for 
African-Americans. 
 Mortality rate due to chronic complications was 
659.1/100,000 person-years for African-Americans. 
NJ 725 Study Cohort (2006)76 
 The overall 3-year crude mortality rate for the whole 
cohort was 8.6% [95% confidence interval (CI) 6.6, 10.6], for 
men 10.6% (95% CI 7.1, 14.1) and for women 7.1% (95% CI 
4.7, 9.5) 
 Diabetes duration, BMI, glycemic control, exercise, and 
presence of other complications were all significant 
predictors/risk factors for mortality; Alcohol consumption 
Chicago T1D Registry (1999)25 
 Annual case-fatality rate was 48.7/100,000 for 
Caucasians 
Allegheny County Registry (2001)26 
 Crude Mortality rate was 571/100,000person-years for 
Caucasians 
 Standardized Mortality Rate was 530/100,000 person-
years for Caucasians. 
Allegheny County Registry (2005)27 
 Crude Mortality rate was 75.2/100,000 person-years for 
Caucasians 
 Mortality rate due to chronic complications was 
311.2/100,000 person-years for Caucasians 
Allegheny County Registry (2010)29 
 Crude Mortality rate was 618.0/100,000 person-years for 
Caucasians 
 
Table 3- Continued 
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was exclusively predictive of mortality in males. 
Allegheny County Registry (2010)29 
 Crude Mortality rate was 1851.3/100,000 person-years 
for African-Americans. 
Note: EDC cohort is approximately 98% Caucasian 
Table 3- Continued 
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Prevention of T1D Complications 
The Diabetes Control and Complications Trial (DCCT) was a hallmark study elucidating the 
prevention of major complications of T1D through intensive diabetes management. Study 
participants were randomized to either conventional therapy (one or two daily insulin injections, 
daily monitoring of blood glucose, 3-month check-ups) or intensive therapy (three or more daily 
insulin injections or insulin pump, at least three blood glucose checks daily, monthly check-ups). 
The intensive intervention group maintained glucose levels close to normal values throughout the 
study. The intensive therapy successfully delayed onset and slowed progression of retinopathy, 
nephropathy, and neuropathy. At the conclusion of the trial, there were no significant differences 
in macrovascular complications, possibly resulting from the young age of the cohort, and 
scarcity of events. 84 As previously mentioned, a later report with over 11 years of post-trial 
follow-up reported a profound decrease in CAD risk in the former intensive treatment group 
(with improved glycemic control) compared to the conventional treatment group. In general, the 
results of this trial provide further evidence of the significant role hyperglycemia plays in 
development and progression of T1D complications, and the potential for prevention.  
In addition to improving glycemic control, other risk factors are potential candidates for 
reducing morbidity of T1D complications. These risk factors often referred to as “modifiable risk 
factors” with glycemic control, include: hypertension, hypercholesterolemia, and smoking. These 
risk factors are modifiable with either clinical treatment or appropriate lifestyle modifications. 
Analysis from the EDC Study indicates that despite improved therapies and interventions to 
address these modifiable risk factors, more efforts are needed to control these factors in patients 
with T1D.85 It is unclear what role, if any, these risk factors may play in the disparity seen 
between African-Americans and Caucasians in T1D health outcomes. In the SEARCH Study, 
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African-American youth diagnosed with T1D were significantly more likely to have higher 
HbA1c levels compared to non-Hispanic white youth, 36% and 12% with poor glycemic control 
respectively.16, 17  
2.5 CHALLENGES EVALUATING RACIAL DIFFERENCES IN TYPE 1 DIABETES 
COMPLICATIONS 
As evident by the preceding discussion, there have been limited epidemiological studies 
investigating variations in the prevalence of major T1D complications among racial/ethnic 
groups, specifically African-Americans compared to Caucasians. Further research is needed to 
assess if racial differences seen in T1D mortality may possibly be attributable to disparities in 
prevalence of complications or risk factors. There are some notable challenges to exploring any 
potential racial differences in both frequency of major complications and risk factors.  
Racial Distribution in Existing Long-term Prospective Cohorts 
The incidence of T1D in African-Americans has historically been lower than Caucasians, and 
though the gap has been reduced, lower rates in African-Americans remains. As such, recruiting 
sample sizes of African-Americans in population based studies large enough to make racial 
comparisons has persisted as a major challenge. The EDC Study cohort has limited racial 
diversity, with only 2% being African-American.31 This number of minority participants, though 
consistent with the demographic profile of the local population and incidence of T1D in African-
Americans, is inadequate to permit any form of ethnic comparisons. The Allegheny County, PA 
Registry cohort has a higher percentage of African-Americans (7.3%), and as previously 
discussed reported significant racial differences in mortality.29 However, the high mortality rate 
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in conjunction with the already low sample size, does not allow for racial comparisons in long-
term complications. In addition, the NJ 725 Study was designed to specifically evaluate T1D 
complications in African-Americans, so all other racial ethnic groups were excluded. While this 
provides substantial information to understanding the morbidity of T1D complications in this 
population, it does not allow for racial comparisons. 
Typology in National Samples/Datasets 
Many national surveys currently collect relevant data from individuals diagnosed with diabetes 
on diabetes complications, other health conditions, health behaviors and risk factors. These 
include the National Health and Nutritional Examination and Survey (NHANES), National 
Health Interview Survey (NHIS), Behavior Risk Factor Surveillance System (BRFSS), and 
Medical Expenditure Panel Survey (MEPS). While these national datasets are very useful, they 
do not clearly distinguish between patients diagnosed with T1D and T2D. Given the differences 
in the pathophysiology of T1D and T2D, it is valuable to investigate differences in the natural 
history of both, including complications and risk factors.   
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3.1 ABSTRACT 
OBJECTIVE - To report the annual incidence of type 1 and type 2 diabetes among youth and to 
describe characteristics of youth diagnosed with diabetes in the United States Virgin Islands 
(USVI).  
RESEARCH DESIGN AND METHODS – All residents ≤19 years of age diagnosed with 
diabetes between January 2001 and December 2010 were identified from review of medical 
records of all hospitals.  
RESULTS – A total of 82 eligible patients were identified and the registry ascertainment was 
estimated to be 98.7% complete. The overall age-adjusted annual incidence rates (per 100,000) 
of type 1 and type 2 diabetes for the study period were 15.3 (95% CI 11.3, 20.1) and 9.6 (95% CI 
6.8, 13.5), respectively. The incidence of type 1 diabetes increased significantly over the study 
period, with an epidemic-like 3-fold increase occurring from 2005 (8.7/100,000) to 2006 
(26.4/100,000) (p=.05). The incidence of type 1 diabetes was highest in the 10-19 age group in 
girls (25.6/100,000), but no age difference was seen in boys, resulting from the lack of a pubertal 
peak in non-Hispanic black boys. The incidence of type 2 diabetes rose significantly between 
2001 (5.3/100,000) and 2010 (12.5/100,000) (p=.03), with the highest incidence occurring in the 
10-19 age group in both boys and girls.  
CONCLUSIONS – The incidence of type 1 and type 2 diabetes in youth is increasing in the 
USVI, similar to global patterns. Further studies are needed to explore the missing pubertal rise 
in type 1 diabetes incidence in non-Hispanic black boys and factors associated with the 
epidemic-like increases observed over the decade. 
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3.2 INTRODUCTION 
Over the past 20 years an increasing incidence of childhood-onset Type 1 and Type 2 diabetes 
has been reported worldwide.11, 12, 86, 87 Standardized population-based registries are commonly 
used tools for monitoring incidence, and further investigation of etiology, risk factors, and 
complications.88 In the late 1980s the U.S. Virgin Islands (USVI) Childhood Diabetes Registry 
was established, along with other registries in over 50 countries, as a part of the World Health 
Organization Multinational Project for Childhood Diabetes DIAMOND Study.21, 89 The 
DIAMOND Study estimated that the worldwide incidence of type 1 diabetes is rising 
approximately 3% annually, with very high global variation. Annual incidence rates in the 1990s 
in youth less than 15 years old ranged from 40.9/100,000 in Finland to 0.1/100,000 in 
Venezuela.11, 12 
Initial studies in the USVI were conducted in 1989. The estimated annual incidence of 
type 1 diabetes for 1979-1988 was 7.5/100,000 (95% CI 4.7,10.3) for persons less than 15 years 
old, with rates being significantly higher in non-Hispanic whites compared to non-Hispanic 
blacks and Hispanics and also higher than rates reported in other Caribbean islands.22 The 
estimated annual incidence subsequently increased to 12.8/100,000 (95% CI 8.1, 18.8) for the 
period 1990-1996.12 The SEARCH for Diabetes in Youth Study, an ongoing effort to monitor the 
incidence of both type 1 diabetes and type 2 diabetes among U.S. youth since 2000, has also 
shown a similar type 1 diabetes pattern, and a dramatic increase in type 2 diabetes. Consistent 
with earlier reports from the USVI, the highest incidence of type 1 diabetes in the SEARCH 
Study was in those in the 10-14 age group, particularly in girls.15 To determine if the global 
increasing incidence of type 1 diabetes is affecting the USVI, we now report data for years 2001-
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2010, including for the first time incidence of type 2 diabetes, along with further exploration of 
gender differences.  
3.3 METHODS 
3.3.1 Study Population 
The U.S. Virgin Islands, a U.S. territory, consist of four inhabited islands (St. Croix, St. Thomas, 
St. John, and Water Island) with a total population of 108,612 individuals. Approximately 76.1% 
of the population are non-Hispanic blacks, and 13.1% are non-Hispanic whites, with the 
remaining being a combination of Hispanic and Asian ethnic groups. The 2000 Census reported 
37,093 individuals less than 19 years old living in the territory.18 
3.3.2 Data Collection 
The detailed methods used to develop the registry have been described in previous reports.21 
Cases were defined as individuals diagnosed with diabetes, age ≤ 19 years, and living in the 
USVI at the time of diagnosis or onset of symptoms. Individuals that were pregnant (likely 
gestational) or on steroid therapy for an existing condition were excluded.  
Primary cases were ascertained through retrospective medical record review at all 
medical centers in the USVI, including 2 hospitals and 3 community health clinics, as of 
December 31, 2010. All diabetes-related ICD-9 codes were queried for individuals less than 20 
years old at the time of the encounter from January 2006 – December 2010. Data were collected 
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using the Childhood Diabetes Registry Data Collection Form, developed in initial registry 
studies and used in subsequent registry updates. Data on race, gender, health insurance, 
clinically-reported diabetes type (Type 1 or Type 2), height, weight, symptoms at diagnosis, 
blood glucose at diagnosis, HbA1C at diagnosis, cholesterol, triglycerides, family history of 
diabetes, and insulin dosage at discharge were collected. Data for some clinical characteristics 
were inconsistently available, however for all cases race, gender, health insurance, diabetes type, 
blood glucose at diagnosis, and insulin dosage at discharge were available. Race was obtained 
from medical records, based on patient self-report, and classified as Non-Hispanic Black, Non-
Hispanic White, Hispanic, or Other.  Health insurance was classified as public (i.e. Medicaid), 
private, or none.  
Degree of case ascertainment was determined using the capture-recapture method, with 
secondary case ascertainment being completed through surveying local medical providers.90 All 
physicians serving pediatric patients, including specialists, were identified through the USVI 
Department of Health Medical Licensing Office. Physicians were contacted via postal, telephone 
and fax with requests for reports of childhood diabetes cases and the associated reporting form. 
In addition, school nurses were all identified through the USVI Department of Education and 
contacted via postal, telephone, and fax with requests. Completed reports were received by the 
USVI Department of Health Bureau of Epidemiology and Surveillance. 94.1% of physicians and 
school nurses submitted completed reports. 
3.3.3 Revalidation of Previous Years 
The accuracy of hospital data for registry case ascertainment has been extensively discussed.91 A 
large majority of population-based childhood diabetes registries rely primarily on hospital data 
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for primary case ascertainment.11, 12 Cases for years 2001-2005 were first ascertained in January 
2006 using the methods described above, but were not formally reported. We re-ascertained 
cases for years 2001-2005, using the same methods described above during this study to 
determine the completeness of the case ascertainment previously conducted.   
3.3.4 Statistical Methods 
Student’s t-test and one-way ANOVA were used to compare continuous variables and the chi-
squares and Fisher’s exact tests were used to compare categorical variables between race groups 
by type of diabetes, with adjustment for multiple comparisons using the Bonferroni correction. 
Annual incidence rates were calculated for each calendar year. There are no intermediate Census 
projections for the USVI since the 2000 U.S. Census; however the Virgin Islands community 
survey reported the estimated population size for years 2001-2005. The Virgin Islands 
community survey is a population-based survey designed to estimate the annual population and 
housing units in the territory, conducted by the Eastern Caribbean Center at the University of the 
Virgin Islands.  These reports indicated an average 1.5% decrease in population size in youth 
(ages 0-19) annually for years 2001-2005.92 The community survey population estimates were 
used to estimate incidence for years 2001-2005 and the annual population size for years 2006-
2010 was estimated assuming that the population decline remained consistent for subsequent 
years. Given the small change in population size annually, there is likely no quantitative bias in 
using this method. In addition, recent U.S. census estimates indicated that the overall USVI 
population declined by 2.0% from 2000 to 2010. 95% confidence intervals were calculated using 
the Poisson distribution of cases. Poisson regression analysis was used to test for differences in 
incidence between years and various sub-groups. Statistical significance was considered as a p-
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value less than 0.05.  For race, gender, and age group comparisons, multiple years were 
combined to make larger numbers available for numerators and denominators allowing greater 
stability of the rate estimates within subgroups. The denominator for multiple year incidence rate 
estimates was the sum of the total population for all respective years. For race comparisons, 
Non-Hispanic White, Hispanic, and Other races were collapsed to a single “Other” race category, 
due to extremely small sample sizes. Weighted moving averages (WMA) of the annual incidence 
rates were calculated using the annual incidence for the previous and following 3 years where 
values closer to the middle of the interval are more heavily weighted than values further in the 
past and future. Statistical analysis was performed using Statistical Analysis Software (SAS, 
Inc.). 
3.4 RESULTS 
A total of 91 newly diagnosed patients 19 years and younger were ascertained during 2001-2010, 
comprising of 57 with type 1 diabetes, 32 with type 2 diabetes, and 2 with gestational diabetes. 7 
cases with type 1 diabetes were excluded because they were not residents of the USVI (typically 
visiting the territory for vacation) and cases with gestational diabetes were not included, resulting 
in 50 cases with type 1 diabetes and 32 cases with type 2 diabetes being included in the analysis. 
Completeness of the ascertainment using capture-recapture methodology and medical provider 
reports as the secondary source was estimated to be 98.7%. 
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3.4.1 Type 1 diabetes 
The estimated annual incidence of type 1 diabetes for the entire study period is 15.3/100,000 
(95% CI 11.6, 20.1). (Table 4) The annual incidence varied throughout the study period ranging 
from 2.8/100,000 (95% CI 0.4, 19.7) in 2003 to 26.8/100,000 (95% CI 14.0, 51.6) in 2007. The 
annual incidence rate of type 1 diabetes in 2010 was 18.7/100,000 (95% CI 8.4, 41.6). The 
WMA illustrates a steady increase in incidence from 2003-2007, which leveled off thereafter. 
(Figure 1A) 
There was no difference in the overall annual incidence of type 1 diabetes between the 0-
9 (11.2/100,000) and 10-19 (19.1/100,000) age groups (p=.19). The incidence was similar in 
both age groups in boys (p=.77), while there was a nearly 2.5-fold increase in the 10-19 age 
group compared to the 0-9 age group in girls, 25.6/100,000 compared to 10.1/100,000 (p=.05). 
(Table 4) 
The annual incidence did not differ for other race groups (10.0/100,000) compared to 
non-Hispanic Blacks (7.4/100,000) in 2001-2005 (p=.65). There was a 3-fold increased 
incidence in non-Hispanic Blacks for the 2006-2010 period (21.4/100,000) (p=.04), compared to 
the 2001-2005 period (7.4/100,000) (p=.03) 
Characteristics of youth diagnosed with type 1 diabetes are shown in Table 5. The largest 
proportion of cases was in the 10-14 age group at diagnosis, with a significantly higher 
proportion of other race youth being diagnosed in this age group compared to non-Hispanic 
black youth (p=.05). The mean HbA1C was significantly higher for non-Hispanic blacks (12.9%) 
compared to other race groups (10.1%) (p=.04), while a similar proportion had HbA1C values 
greater than 9.5% at diagnosis (p=.44). 100% of youth diagnosed with type 1 diabetes initiated 
insulin therapy at diagnosis.  
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3.4.2 Type 2 diabetes 
The annual incidence of type 2 diabetes ranged from 2.8/100,000 (95% CI 0.4, 20.0) in 2003 to 
18.2/100,000 (95% CI 8.2, 40.4) in 2008. The annual incidence increased sharply from 2003-
2007, and leveled off thereafter, shown in Figure 1B. The incidence of type 2 diabetes was 
significantly lower in the 0-9 age group (2.5/100,000) compared to the 10-19 age group 
(16.1/100,000) (p=.01). (Table 4) The incidence increased nearly 2.5 times from 2001-2005 to 
2006-2010 periods for non-Hispanic Black youth (p=.05). There were no cases of type 2 diabetes 
in other race groups during 2001-2005, yet the incidence increased to 23.7/100,000 in 2006-
2010. The overall incidence of type 2 diabetes increased significantly from 2001-2005 to 2006-
2010 (p=.03). (Figure 1B)  
Non-Hispanic black youth had a significantly higher mean HbA1C (p=.05), compared to 
other race youth, while a similar proportion had HbA1C values greater than 9.5% at diagnosis 
(p=.69). Nearly two times more non-Hispanic black youth were uninsured compared to other 
race youth (p=.04). (Table 5) 
The incidence of type 1 diabetes (11.19/100,000) is significantly higher than the 
incidence of type 2 diabetes (2.49/100,000) in the 0-9 age group (p=.02). (Table 4) 
3.5 DISCUSSION 
The incidence of childhood diabetes has increased significantly in the USVI over the past 
decade, compared to published rates from the 1980s and 1990s.11, 22 This finding is consistent 
with general increases in childhood diabetes noted around the world.11, 12, 86, 87 Despite some 
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variation, the rates of type 1 diabetes and type 2 diabetes have more than doubled in the territory. 
A rapid epidemic-like rise in incidence of type 1 diabetes and type 2 diabetes occurred around 
2005, in which the incidence rates for the following years were nearly 2 times higher than the 
years prior. While the rapidly rising rate of childhood obesity is likely a major contributor to the 
increase in type 2 diabetes, the reason for the epidemic like increase in type 1 diabetes incidence 
is less clear; however a similar epidemic-like increase of type 1 diabetes was reported in the 
USVI in the 1980s.22 Gender differences may play a role in this particular epidemic-like 
increase. The annual incidence for boys in the USVI was much lower in the earlier half of the 
decade prior to the epidemic-like increase, but a sharp increase in incidence in boys occurred 
between 2005 (11.6/100,000) and 2007 (35.96/100,000). Incidence rates in boys remained high 
in the latter half of the decade, and were no longer lower than rates in girls. Epidemic-like 
increases in incidence of type 1 diabetes have been reported in other studies in the US.93, 94 While 
these epidemic-like increases remain largely unexplained, some attribute concomitant changes in 
incidence of viruses that have been associated with triggering the onset of type 1 diabetes.95 
Additional studies are needed to identify the factors that might be responsible for the epidemic-
like increases in type 1 diabetes.  
Historically, the issue of childhood obesity has not been associated with type 1 diabetes, 
as these youth were more commonly underweight and underdeveloped at diagnosis; however 
recent data suggest that the prevalence of obesity in youth with type 1 diabetes is increasing.96, 97, 
98 This may also be a contributor to the increasing incidence of type 1 diabetes in the USVI. 
Equal amounts of youth (20%) were classified as underweight and overweight at diagnosis in 
this study; though this observation is limited by the classification of weight being determined by 
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health professional report and not actual BMI measurement (due to large amount of missing 
height and weight data in medical records). 
An increase in the incidence of non-Hispanic black cases of type 1 diabetes also appears 
to be a major contributor to the overall increase of type 1 diabetes in the USVI. In 1988, the 
incidence of type 1 diabetes in non-Hispanic Blacks was 5.8/100,000, compared to 21.4/100,000 
in 2006-2010, a nearly 3.5-fold increase. Figure 2 illustrates the increasing incidence of type 1 
diabetes in non-Hispanic Blacks in various population-based registries in the U.S. and Caribbean 
throughout the last three decades.5,11, 12, 15, 22, 93, 94, 98, 99, 100, 101, 102 The incidence rate for the first 
half of the decade in the USVI (8.1/100,000)  are lower than the incidence rates for the first half 
of the decade found in the SEARCH study (15.7/100,000); however, the rates for the latter half 
of the decade in the USVI are much higher (20.4/100,000). Recent data from SEARCH is not 
available so it is unclear if this increase occurred in the contiguous US as well. The incidence 
rate in other race groups has slightly decreased to 23.7/100,000 in 2006-2010, compared to 
28.9/100,000 in 1988.22 This decreasing incidence in other race groups in the USVI may be 
attributed to the low population of non-Hispanic white youth and adults of child-bearing age in 
the territory and the increasing population of Hispanics, who are included in the other race 
groups and commonly have lower rates of type 1 diabetes.  
Consistent with previous studies, girls had higher overall rates of both type 1 diabetes and 
type 2 diabetes.5,22, 94 In the SEARCH Study, non-Hispanic black girls had nearly 2-fold higher 
incidence compared to non-Hispanic Black boys.5 In the present study, the highest incidence of 
type 1 diabetes in non-Hispanic black girls occurred in the 10-14 age group, consistent with the 
well-recognized pubertal/adolescent peak seen in many studies.5, 22, 94, 100, 101 However, there was 
no such peak for non-Hispanic black boys with rates for 5-9, 10-14, and 15-19 age groups being 
40 
 
virtually identical. (Table 4) This male pattern is intriguingly inconsistent with the commonly 
reported significant pubertal rise in type 1 diabetes incidence. However, this finding is similar to 
those reported in SEARCH where the incidence of type 1 diabetes is significantly higher in non-
Hispanic black girls in the 10-14 (pubertal) age group (26.1/100,000), compared to the 5-9 (pre-
pubertal) age group (20.9/100,000); however in non-Hispanic black boys the respective rates are 
17.8/100,000 and 16.7/100,000.5 Further investigation is needed to explain why non-Hispanic 
Black boys seem to be protected from the traditional pubertal rise seen in type 1 diabetes.   
The overall incidence of type 1 diabetes in the USVI for the study period (2001-2010) is 
slightly lower (15.3/100,000) than recent results from the SEARCH study, which estimated the 
incidence for the U.S. to be 19.0/100,000 in 2002-2003.5 This lower rate in the USVI is 
expected, given the historically lower rates of type 1 diabetes in non-Hispanic blacks in the 
Caribbean; however, you may predict a more drastic difference, as is the case with other black 
African-heritage populations in the Caribbean.12, 23, 102 There are limited current population-based 
data on the incidence of childhood diabetes throughout the Caribbean, which makes comparison 
with other similar geographical and cultural populations difficult. However, earlier results from 
the DIAMOND Study and other Caribbean studies showed lower rates of type 1 diabetes 
throughout the Caribbean islands, compared to the USVI and US.12, 102 (Figure 2)  
The incidence rates of type 2 diabetes were not reported in early studies in the USVI as 
there were low to no cases occurring. The low incidence of type 2 diabetes found in earlier 
studies is unlikely due to diagnosis taking place in physician offices, as local physicians were 
also surveyed for validation. The incidence rate of type 2 diabetes (9.6/100,000) in the USVI is 
nearly two times higher than the estimated incidence in the US (SEARCH Study-5.8/100,000) 
and the Chicago Childhood Diabetes Registry (5.0/100,000).5, 100 The increasing rates of type 2 
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diabetes may be partly attributed to the higher overall rates in girls, who are more likely to be 
overweight and obese, a primary risk factor for type 2 diabetes.17, 103, 104 A higher proportion of 
youth with type 2 diabetes were overweight at diagnosis compared to youth with type 1 diabetes. 
However, similar to the SEARCH Study, more non-Hispanic black youth with type 1 diabetes 
were overweight at diagnosis compared other race groups.17, 104 There are currently no data 
available on the long-term health outcomes of individuals diagnosed with type 1 diabetes in the 
USVI; however, results from U.S. studies have indicated that non-Hispanic blacks are at 
increased risk for premature mortality.25, 27, 105 A recent study reported excess risk of 
cardiovascular risk factors for adolescents with type 1 diabetes who were also overweight.106 The 
higher rates of obesity in non-Hispanic black youth with type 1 diabetes may possibly further 
increase the disparity seen in long-term health outcomes. 
The USVI Childhood Diabetes Registry, a population-based registry, is the primary 
source of data on the rates and trends of childhood diabetes in the territory. Similar to other 
studies, we utilized data from medical records to update the registry.5, 11, 12, 23, 93, 94, 99, 100, 101, 102 
This presents several limitations for consideration. First, we relied on health care professional 
diagnosis to categorize the diabetic phenotype. The issue of typology remains a challenge for 
epidemiological studies. There are several factors contributing to this issue: (1) the mean age of 
diagnosis seems to be increasing thereby limiting the use of age as an indicator, (2) childhood 
obesity rates are increasing in all races and age groups, (3) lack of standardized diagnostic 
criteria, and (4) no definitive laboratory test to determine phenotype. The local health system of 
the USVI, addresses this dilemma in some ways. There are only 2 hospitals where individuals 
can seek medical care in the territory. The often acute onset of childhood diabetes leads for the 
need to seek emergency care and hospitalization. The small number of health care facilities and 
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medical professionals limits the variation in diagnostic methods, compared to similar studies 
involving larger number of centers and geographic locations. In the SEARCH Study, which also 
used physician diagnosis to classify diabetes type, the physician diagnosis abstracted from 
medical records corresponded well with autoantibody and c-peptide measures collected in the 
study follow-up.17, 104 
The second issue that arises from use of medical record review is incomplete 
ascertainment. We used the capture-recapture method to estimate the completeness of 
ascertainment. Again, the limited number of health care professionals in the territory allows for 
maximal re-ascertainment of cases. There are two endocrinologists providing care to the majority 
of children with diabetes in the territory, which increases the likelihood of ascertaining all cases. 
However, there are an increasing number of pediatricians and family medicine physicians that 
are diagnosing and providing care for youth with type 2 diabetes. This is evident in the re-
ascertainment of cases diagnosed in years 2001-2005. There was a significant increase in cases 
of type 2 diabetes and the majority of the cases not captured at the initial ascertainment, were 
individuals who were diagnosed by a local physician and only later seen in the hospital for 
diabetes complications. As such, we may be underestimating the actual incidence. 
Finally, this analysis was limited by the small number of cases in various sub-groups, 
including age and race categories. For example, we were unable to create smaller age categories 
as are commonly reported (0-4, 5-9, 10-14, and 15-19), or analyze differences between non-
Hispanic whites and Hispanics.  
In conclusion, we report the annual incidence of childhood diabetes in the USVI for all 
age groups and races, which shows an increasing incidence of both type 1 diabetes and type 2 
diabetes throughout the territory. In addition, these data also suggest non-Hispanic black boys do 
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not have a pubertal peak in type 1 diabetes incidence, a finding consistent with previous studies. 
As previously discussed, the local health care system has limited infrastructure to manage high 
volumes of youth with diabetes. With the majority of youth with diabetes being uninsured or 
having public health insurance, continued monitoring of the rates and trends, and further studies 
evaluating the overall burden of childhood diabetes in the USVI, including morbidity and 
mortality, are critical to improving the health outcomes and developing strategies for prevention.   
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3.6 TABLES 
Table 4: Annual incidence (per 100,000) of type 1 and type 2 diabetes in the USVI by gender and age group 
(2001 – 2010) 
 
 
 Boys 
 
 Girls 
 
 Total  
 
 
 
n Incidence (per 
100,000) 
 (95% CI) 
n Incidence (per 
100,000) 
 (95% CI) 
n Total  
(95% CI) 
Type 1       
     0-9 years  10 12.3 
(6.6, 22.9) 
8 10.1 
(5.0, 20.1) 
18 11.2 
(7.1, 17.8) 
     10-19 years 11 12.6 
(7.0, 22.7) 
21 25.6† 
(16.9, 38.9) 
32 19.0 
(13.5, 26.8) 
     All (0 - 19 
years) 
21 12.4 
(8.1, 19.1) 
29 18.1 
(12.7, 25.9) 
50 15.3 
(11.6 , 20.1) 
Non-Hispanic 
Blacks 
      
     0-4 years 3 8.4 
(2.7, 26.1) 
2 5.9 
(1.5, 23.8) 
5 7.2 
(3.0, 17.4) 
     5-9 years 6 14.2 
(6.3, 31.6) 
5 12.0 
(5.0, 28.8) 
11 13.1 
(7.3, 23.7) 
     10-14 years 5 12.7 
(5.3, 30.6) 
10 25.0 
(13.4, 46.4) 
15 18.9 
(11.4, 31.4) 
     15-19 years 6 14.9 
(6.9, 31.9) 
5 13.7 
(5.7, 32.9) 
11 14.3 
(8.5, 26.6) 
Type 2       
     0-9 years 2 2.5 
(0.6, 9.8) 
2 2.5 
(0.6, 10.1) 
4 2.5 
(0.9, 6.6) 
     10-19 years 10 11.4† 
(6.1, 21.2) 
18 21.0† 
(13.2, 33.3) 
28 16.1† 
(11.1, 23.4) 
     All (0 – 19 
years) 
12 7.1 
(4.0, 12.5) 
20 12.1 
(7.8, 18.7) 
32 9.6 
(6.8, 13.5) 
† - p<0.05 (Based on Poisson regression analysis for comparison between 0-9 and 10-19 age groups within gender 
groups) 
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Table 5: Demographic and clinical characteristics at diagnosis of youth with type 1 and type 2 diabetes in 
USVI by race (2001-2010) 
 Type 1 diabetes Type 2 diabetes 
 Non-Hispanic 
Black 
Other Non-Hispanic 
Black 
Other 
n (%) 41 (82) 9 (18) 26 (81.2) 6 (18.8) 
% Male 46.3 22.2 † 38.5 33.3 
Age of diagnosis (years) 10.86 ± 4.8 11.93 ± 4.1 14.24 ± 3.61 13.49 ± 4.6 
Age of diagnosis categories (%)     
     0-4 12.2 11.1 3.8 --- 
     5-9 29.3 --- 3.8 33.3 
     10-14 31.7 66.7 † 46.2 33.3 
     15-19 26.8 22.2 46.2 33.3 
Body Weight Phenotype (%)     
     Underweight 17.1 22.2 --- --- 
     Normal Weight 61.0 66.7 11.5 --- 
     Overweight 22.0 11.1 88.5 100 
Blood Glucose at diagnosis 504.2 ± 238.0 436.1 ± 149.8 386.9 ± 218.6 426.8 ± 165.5 
Blood Glucose > 200 at diagnosis (%) 100 88.9 73.1 66.7 
HbA1c (mean) 12.9 ± 1.7 10.1 ± 1.0 † 11.2 ± 1.0 9.25 ± .9† 
HbA1C ≥ 9.5 at diagnosis (%) 46.7 44.4 61.5 66.7 
Urine Ketones present at diagnosis 
(%) 
34.1 33.3 34.6 33.3 
Insulin at diagnosis (%) 100 100 46.2 50.0 
Insurance (%)     
    Private 26.8 33.3 42.3 50.0 
    Public 41.5 44.4 26.9 33.3 
    None (Self-Pay) 31.7 22.3 30.8 16.7† 
† - p<0.05 (Student t-test for continuous variables and χ2 for categorical variables for comparison between race 
groups within diabetes type) 
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3.7 FIGURES 
A             B 
     
Figure 1: Annual incidence (per 100,000) of type 1 (A) and type 2 (B) diabetes in USVI by year (2001-2010) 
 
Figure 2: Annual incidence (per 100,000) of type 1 diabetes in non-Hispanic black youth <15 Years old in U.S. 
and Caribbean 
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4.1 ABSTRACT 
OBJECTIVE: Type 1 diabetes remains a significant source of premature mortality; however, its 
burden has not been assessed in the U.S. Virgin Islands (USVI) 
RESEARCH DESIGN AND METHODS: We report overall and 20-year mortality in the USVI 
Childhood (<19 years old) Diabetes Registry Cohort diagnosed 1979-2005. Recent data for non-
Hispanic blacks from the Allegheny County population-based registry were used to compare 
mortality in the USVI to the contiguous US. USVI non-Hispanic black population mortality data 
were used to calculate standardized mortality ratios (SMRs) for non-Hispanic blacks. 
RESULTS: As of December 31, 2010, the vital status of 94 of 103 total cases was confirmed 
(91.3%) with mean diabetes duration 16.8 ± 7.0 years. No deaths were observed in the 2000-
2005 cohort. The overall mortality rates for those diagnosed 1979-1989 and 1990-1999 were 
1852 and 782 per 100,000 person-years, respectively. Survival was worse for individuals 
diagnosed >14 years old (47%) compared to those diagnosed <10 years (95%, p=.03) and those 
10-14 years old (80%, p=.09). The 20-year mortality and survival in non-Hispanic blacks did not 
differ between the USVI and Allegheny County cohorts. The overall SMR for non-Hispanic 
blacks in the USVI was 5.8 (95% CI 2.7-8.8), compared to 7.5 (95% CI 5.2-9.8) in Allegheny 
County. 
CONCLUSIONS: This study, as the first type 1 diabetes mortality follow-up in the USVI, 
confirmed previous findings of poor disease outcomes in racial/ethnic minorities with type 1 
diabetes. Continued follow-up and efforts to improve disease management and access to care in 
the USVI are critical. 
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4.2 INTRODUCTION 
Unlike type 2 diabetes, where prevention is possible107, type 1 diabetes (T1D) is currently a 
lifelong incurable metabolic disorder. Despite increased access to treatment, improved disease 
management, and successful reduction of complications through intensive therapy108,  the major 
complications of type 1 diabetes (retinopathy, nephropathy, neuropathy, and cardiovascular 
disease) persist as significant sources of morbidity and early mortality.47 Prior mortality studies 
estimate T1D mortality in the U.S. to be 5-7 times higher than the general population109; higher 
than estimates in other developed nations.26, 110 Recent reports from the Allegheny County 
population-based registry indicated that T1D mortality has improved in recent decades and the 
proportion of deaths due to often preventable acute complications has greatly decreased.29, 105 
Researchers also confirmed that African-Americans with T1D were at a nearly 2.5-fold increased 
risk of premature death compared to Caucasians, as shown in several earlier studies.24, 25, 27, 28 
Roy et al also reported long-term T1D mortality to be 6-12 times higher in an all-African-
American cohort compared to the general population.76 Thus, further assessment and 
understanding of the mortality associated with T1D in non-Hispanic blacks is critical. The 
United States Virgin Islands (USVI), a predominantly non-Hispanic black population, provides 
an ideal population. Diabetes has risen to the fourth leading cause of death in the USVI111; 
however, the mortality and survival associated specifically with T1D has yet to be evaluated and 
is of concern as the incidence of T1D in the USVI has risen over the past 30 years to levels 
higher than anticipated based on worldwide estimates.11, 22 
  We thus investigated mortality rates in a population-based childhood onset T1D cohort 
in the USVI with a mean follow-up of ≥15 years to assess trends in mortality by race, sex, age of 
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diagnosis, and year of T1D diagnosis and to compare rates to the non-Hispanic black cohort of 
the Allegheny County T1D Registry.  
4.3 METHODS 
4.3.1 Study Population 
The USVI Childhood Diabetes Registry cohort includes any individual diagnosed with diabetes 
before age 19 and living in the territory at the time of diagnosis between January 1, 1979 and 
December 31, 2005.21 Cases were ascertained through retrospective review of medical records at 
all hospitals and community health clinics. Individuals were excluded if pregnant (likely 
gestational diabetes) or not a USVI resident. Diabetes type was determined by health 
professional diagnosis. The registry cohort is composed of a total of 103 eligible T1D cases from 
all three islands (St. Croix, St. Thomas, and St. John). 
4.3.2 Vital Status Ascertainment 
Vital status was ascertained as of December 31, 2010, by first contacting all participants via 
postal mail and telephone to update registry contact information. When participants were not 
contactable via telephone or mail, attempts were made to contact family members listed in the 
registry via telephone. Finally, telephone books and internet search engines were used to identify 
updated contact information for participants. 
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 The USVI Territorial Death Index, the U.S. Social Security Death Index (SSDI), and 
the National Death Index (NDI) were then searched to confirm possible deaths among non-
contacted participants. Death certificates were obtained from the USVI Bureau of Vital Statistics 
for all deaths occurring within the territory. NDI data was ascertained for all deaths occurring 
outside of the territory, to determine cause of death.  
4.3.3 Statistical Analysis 
Student’s t-test and one-way ANOVA were used to compare continuous variables across groups 
(sex, race, and diagnosis cohort), adjusting for multiple comparisons using the Bonferroni 
correction. The χ2 (or Fisher’s exact) test was used to compare categorical variables between 
groups. Diagnosis year was categorized into three groups, based on decade (1979–1989, 1990–
1999, and 2000-2005) to assess temporal trends in overall mortality. Age at diagnosis was 
categorized as pre-pubertal (<10 yrs), peri-pubertal (10-14 yrs), and post-pubertal (>14 yrs). 
Race was categorized as non-Hispanic white (NHW), non-Hispanic black (NHB), and Hispanic 
(H), based on race abstracted from the USVI Childhood Diabetes Registry. Mortality rates were 
estimated using person-years method, and 95% CIs were determined using the Poisson 
distribution.  Non-Hispanic whites were not included in the analysis, because no deaths have 
occurred to date. Each individual’s person-years contribution was calculated from the date of 
diagnosis to the December 31, 2010, date of death, of the date of last follow-up.  Life-table 
analyses by the Kaplan-Meier method were performed. Log-rank test was used to determine the 
statistical difference between survival curves by sex, race, diagnosis cohort, and age of 
diagnosis. Age- and sex-adjusted standardized mortality ratios (SMRs) were calculated as the 
observed divided by the expected number of deaths in each age, and sex category for non-
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Hispanic Blacks. Expected mortality was calculated using population life tables for USVI, 
obtained from the USVI Department of Health Bureau of Vital Statistics.112 Background 
mortality rates covering the same period were used. SMRs were not calculated for Hispanics due 
to the lack of population life tables for Hispanics in the USVI. 95% CIs were determined with 
the Poisson distribution. Mortality rates and SMRs were compared using rate ratio (RR) analyses 
and calculating 95% CIs.113 Multivariate Cox proportional hazard models were used to assess the 
effects of sex, race, age at onset and year of diagnosis on mortality. Twenty (20)-year mortality 
rates in NHBs in the USVI cohort were compared to all-cause mortality rates in NHBs in the 
Allegheny County population-based T1D registry cohort, as a proxy for the contiguous US. 
Statistical significance was considered as a p-value less than 0.05. Analyses were completed 
using SPSS 18.0 (SPSS, Inc.) and SAS 9.2 (SAS, Inc.). 
4.4 RESULTS 
As of December 31, 2010, the vital status of 94 of the 103 total cases was confirmed (91.3%); 
though only 69 of 75 (92.0%) cases diagnosed 1979-1999 were confirmed and included in the 
analysis. There were no statistical differences in the proportion of males (46.9% male vs. 50.1% 
male) or mean age at onset (11.5 ± 4.4 vs. 11.0 ± 2.4) in the unverified sample, compared to the 
verified sample. Non-Hispanic blacks (94.7%) and Hispanics (90%) had similar proportions 
traced. However, individuals diagnosed 1979-1989 (80.6%) were less likely to be traced 
compared to the 1990-1999 (95.6%) and 2000-2005 (100.0%) cohorts (p=.04).  Demographic 
characteristics and overall mortality rates of the USVI type 1 diabetes cohort are shown by sex, 
race, and year of diagnosis in Table 6.  
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The overall mortality rate was 1170 per 100,000 person-years (95% CI 727, 1883). There were 
no significant differences in overall mortality by sex, race, diagnosis cohort or age of onset in the 
USVI. 
 Results from Cox regression modeling showed that sex, race, and year of diagnosis 
were not significant and were not included in the final model. (Table 7) Age at onset, 
categorically and continuously, was the only significant predictor of mortality in the cohort. 
Individuals diagnosed after the age of 14 had a 9-fold increased risk of mortality compared to 
those diagnosed prior to age 10 (95% CI 2.0-42.3). The 10-14 age group had a nearly 4-fold 
increased risk, though not significant (95% CI 0.5-15.8). Each additional year in age at onset 
increased risk of mortality by 23% (hazard ratio – 1.2, 95% CI 1.1-1.4). 
 Survival curves up to 20 years duration by sex, race, diagnosis cohort, and age of 
diagnosis based on the Kaplan-Meier method are shown in Figure 3. Overall cumulative survival 
was 98% at 10 years, 91% at 15 years and 73% at 20 years. No difference was seen by sex, race, 
or diagnosis cohort. Individuals diagnosed age ≥14 had poorer survival compared to both the <10 
and 10-14 age at onset groups (p=.03). Survival at 20 years for the <10, 10-14, and >14 age at 
onset groups was 95%, 80%, and 47%, respectively.  
 The 20-year mortality rates by sex, diagnosis year, and age of diagnosis for NHBs in 
the USVI and Allegheny County, PA are shown in Table 8.The 20-year mortality rate in NHBs 
did not differ between the USVI and Allegheny County, PA cohorts (p=.23). The overall SMRs 
for NHBs are also shown in Table 8. The overall SMR for non-Hispanic blacks in USVI was 5.8 
(95% CI 2.7-8.8). There were no differences based on sex, diagnosis cohort, or age of diagnosis; 
however the SMR was highest for the 1979-1989 cohort (8.1, 95% CI 3.1-13.1) and for the >14 
diagnosis age group (8.7, 95% CI 2.3-15.1). The SMR seemed to increase gradually by age of 
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diagnosis; however this pattern was not observed in Allegheny County, PA, with the highest 
SMR occurring in the <10 age group. 
 Survival curves up to 20 years duration comparing NHBs in the USVI to NHBs in 
Alleghany County are shown in Figure 4 There was no differences in cumulative survival 
between non-Hispanic blacks in the USVI and Allegheny County, PA cohort. 
4.5 DISCUSSION 
This study, for the first time, evaluated mortality in a population-based type 1 diabetes cohort in 
the USVI and compared the effects of race, sex, age of diagnosis, and calendar year period of 
diagnosis on survival. These data appear to reveal a major impact of age at onset on mortality, 
such that a post-pubertal onset increases mortality 9-fold; however, due to the small sample size, 
this was not statistically significant. Recent data from the Allegheny County, PA population-
based registry cohort were also used to compare the mortality experience in the USVI to that of a 
county in the contiguous United States. Notably, there were no significant difference in 20-year 
mortality or survival for non-Hispanic blacks in the USVI cohort compared to non-Hispanic 
blacks in the Allegheny County, PA cohort, suggesting a similar mortality experience for non-
Hispanic blacks across the different geographic locations. In accordance with reports from 
Allegheny County, PA cohort26, 105 and other studies76, 114 that have shown higher mortality in 
individuals with type 1 diabetes compared to the general population, mortality for non-Hispanic 
blacks with type 1 diabetes in the USVI was 5.8 (95% C.I. 2.7-8.8) times higher than the general 
USVI non-Hispanic black population. This SMR was similar to that of non-Hispanic blacks in 
the Allegheny County, PA cohort (SMR: 7.5 (95% C.I. 5.2-9.8)).  
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 The paradox of comparable SMRs for non-Hispanic blacks and non-Hispanic whites, 
despite dramatically higher mortality rates in non-Hispanic blacks observed in Allegheny 
County, PA remains unclear. Unfortunately, too few non-Hispanic whites in the USVI precluded 
examination of this in the USVI. Nonetheless, the higher background mortality in Allegheny 
County, PA in non-Hispanic blacks compared to non-Hispanic whites in general was attributed 
to violent and accidental deaths in non-Hispanic blacks, and the absence of such deaths in the 
type 1 diabetes population.105 This may also be a contributor in the USVI as well, as violent 
crimes (specifically assault/homicide) remain the third leading cause of death, accounting for 
approximately 7% of the deaths annually, but none of the deaths in the USVI cohort were due to 
violence; in fact, similar to Allegheny County, PA, all deaths in non-Hispanic blacks were due to 
diabetes-related acute and chronic complications.111 Moreover, based on national estimates non-
Hispanic blacks without type 1 diabetes are at greater risk compared to non-Hispanic whites for 
renal disease in the general population, also a major cause of death in the general population the 
USVI.111, 112, 115, 116 As such, it is likely a combination of these factors contributing to the excess 
mortality in the general non-Hispanic black population, resulting in no observed disparity in the 
overall impact of type 1 diabetes between whites and blacks.  
 In addition, poorer outcomes in non-Hispanics blacks with type 1 diabetes may also be 
associated with poor socioeconomic status and other environment factors, including access to 
care. The SEARCH Study found that non-Hispanic black youth diagnosed with type 1 diabetes 
had poorer socioeconomic profiles, and were more likely to be uninsured or utilizing public 
insurance.17 In concert, the USVI has high rates of poverty and uninsured, coupled with a 
significantly high cost of living, which results in poor overall socioeconomic conditions.117 The 
poor socioeconomic conditions impact the entire population, with and without diabetes, but are 
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likely to still be associated with poor prognosis and increased mortality in type 1 diabetes118, and 
would not be detected in the SMR.  
 Mortality between non-Hispanic blacks and Hispanics did not differ, but the sample 
size of the latter precludes further analysis. Regrettably, apart from this study, there is no long-
term follow-up of mortality in Hispanics with type 1 diabetes in the literature.   
No sex differences in mortality for men and women was observed in the USVI, consistent with 
several previous studies,109, 76, 118 but not all110, 119 In the New Jersey 725 Study there were no 
significant differences in mortality for men and women; however the SMR for women was 
significantly higher than for men (10.5 vs. 7.0).76 This difference was not observed in the USVI, 
as SMRs for men and women were virtually identical (6.0 vs. 5.5); however, a difference was 
seen in the Allegheny County cohort, where females had a nearly 4-fold increased SMR 
compared to males (4.0 vs. 15.6). This may be attributed to the smaller sex gap in overall 
mortality seen in the general non-Hispanic black population in the USVI compared to Allegheny 
County and New Jersey.  
 In contrast to the overall Allegheny County, PA cohort and other studies abroad110, 120 , 
no temporal improvement in mortality was observed in the USVI, as there were no significant 
differences in mortality based on diagnosis cohort. Importantly, follow-up was worse for the 
earlier diagnosis cohort (80.6% vs. 95.6%). As such, we evaluated the mortality and survival, 
applying the same mortality in the traced individuals to the untraced individuals, as well as 
estimated mortality assuming that all untraced individuals were deceased, and mortality (p-
values: 0.27, 0.21) and survival (p-values: 0.62, 0.41) still did not significantly differ. Notably, in 
Allegheny County, PA, there was also no significant temporal improvement in mortality for non-
Hispanic blacks, as survival did not differ across diagnosis year cohorts.  Interestingly, while 
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overall mortality did not differ between diagnosis cohorts, survival, particularly at 10-15 years 
duration, seemed worse for the later diagnosis cohort (1990-1999, 90.0%  at 15 years) compared 
to the earlier diagnosis cohort (1979-1989, 96.1% at 15 years) in the USVI, though this 
difference was not significant. While this may partly be an artifact of the small sample size, it is 
plausible that there has been no temporal improvement in mortality in the USVI. While disease 
recognition, care and treatment have improved, there are still major gaps in access to specialized 
diabetes care and treatment. There are few endocrinologists currently practicing in the territory, 
and none specializing in pediatrics.121  There is also minimal access to diabetes educators to 
provide additional training to patients and families. As a result, families often seek care in 
neighboring territories or stateside; however, this is limited to those financially advantaged 
families, as this is often not covered by medical insurance providers and in cases where coverage 
is provided, travel expenses remain the burden of the individual family.  
 Age of diagnosis was the only significant predictor of mortality in the USVI, with a 
significantly better survival in those diagnosed before puberty (<10) compared to those 
diagnosed during the pubertal (10-14) (p=.09) and post-pubertal (>14) (p=.03) periods. This 
difference also seemed to occur specifically in non-Hispanic blacks, as 20-year mortality 
increased by 4.5-fold between the <10 age group and the >14 age group; this difference was 
significant. The overall SMRs also seemed to follow a similar pattern as the SMR in the <10 age 
group was 2.6, compared 8.7 in the >14 age group (not significant). This pattern was not 
observed in non-Hispanic blacks in Allegheny County, PA, where the SMRs did not differ 
dramatically across diagnosis age groups. Other studies have shown higher mortality rates in 
individuals diagnosed during and after puberty, compared to those diagnosed before puberty.109, 
110, 119, 122  While the factors associated with this increased risk remain unclear, and it is possible 
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that care-related factors play a role (e.g. resistance to self-management and compliance by 
maturing adolescents). In addition, there is some evidence that suggests that the earliest years of 
type 1 diabetes (pre-puberty) are largely free of complications, and as such, the pattern seen may 
be an effect of age, as opposed to a true difference in mortality. 
 The major limitation of this present study is the small sample size and as a result no 
confirmed deaths were seen in non-Hispanic whites. This prohibited racial comparisons between 
non-Hispanic whites and other race groups in the USVI. However, based on survival estimates 
for non-Hispanic whites in Allegheny County, PA, we would expect 92% survival at 24-years 
duration (mean duration of non-Hispanic whites in USVI), which equates to only .48 expected 
deaths. Another limitation of the study is that the living status of 8.7% of participants was not 
determined. Nonetheless, the likelihood of death in these individuals is low, as the USVI 
Territorial Death Index, Social Security Death Index, and National Death Index were all 
searched for these individuals. A final limitation for consideration is the impact of migration 
from the USVI to the contiguous US on the interpretation of these results specific to factors in 
the USVI. Approximately 35% of deaths occurred outside of the USVI; however, some of this is 
accounted for by individuals seeking ambulatory care stateside.    
 In conclusion, this is the first population-based type 1 diabetes mortality follow-up in 
the USVI and Caribbean region. This study confirms previous findings of poor disease outcomes 
in racial/ethnic minorities with type 1 diabetes, particularly if diagnosed after puberty. Mortality 
outcome seems however comparable to Allegheny County, PA non-Hispanic blacks. Continued 
follow-up and efforts to improve disease management and access to care in the USVI are critical. 
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4.6 TABLES 
Table 6: Demographic Characteristics and Overall Mortality of USVI Type 1 Diabetes Registry Cohort (1979-2005) by Sex, Race, and Year of Diagnosis 
 Sex Race Year of Diagnosis  
 Male* Female Non-
Hispanic 
Black* 
Non-
Hispanic 
White 
Hispanic 1979-1989* 1990-1999 2000-2005 Total 
n 49 54 77 6 20 36 45 22 103 
Follow-up 89.8 (44) 92.6 (50) 94.7 (72) 50 (3) 90 (18) 80.6 (29) 95.6 (43) 100.0 (22)† 91.3 
Male -- -- 48.1 (37) 66.7 (4) 40.0 (8) 55.6 (20) 44.4 (20) 40.9 (9) 47.6 (49) 
Age of diagnosis (years) 10.9 ± 4.7 11.7 ± 4.4 11.6 ± 4.7 8.8 ± 2.4 11.1 ± 4.5 10.9 ± 4.4 11.2 ± 5.2 12.4 ± 3.2 11.3 ± 4.5 
Mean diabetes duration 
(years) 
17.5 ± 7.2 16.1 ± 6.9  16.7 ± 7.0 23.8 ± 2.7 15.4 ± 7.0 24.3 ± 4.2  15.2 ± 3.0‡ 7.5 ± 1.5‡ 16.8 ± 7.0 
Mean Age (years) 28.4 ± 7.3 27.8 ±7.8 28.3 ± 7.4 32.6 ± 4.5 26.5 ± 8.6 35.2  ±5.2 26.4 ± 5.3† 19.9 ±3.3‡ 28.2 ± 7.5 
Diagnosis Cohort          
     1979-1989 40.8 (20) 29.6 (16) 31.2 (24) 83.3 (5) ‡ 35.0 (7)† -- -- -- 35.0 (36) 
     1990-1999 40.8 (20) 46.3 (25) 48.1 (37) 16.7 (1) † 35.7 (7) -- -- -- 43.7 (45) 
     2000-2005 18.4 (9) 24.1 (13) 20.8 (16) -- 30.0 (6) -- -- -- 21.4 (22) 
Race          
     Non-Hispanic Black 8.2 (4) 3.7 (2) -- -- -- 66.7 (24) 80.0 (36) 72.7 (16) 5.8 (6) 
     Non-Hispanic White 75.5 (37) 74.1 (40) -- -- -- 13.9 (5) 2.2 (1) -- 74.8 (77) 
     Hispanic 16.3 (8) 22.2 (12) -- -- -- 19.4 (7) 15.6 (7) 27.3 (6) 19.4 (20) 
Deaths 20.4 (10) 13.0 (7) 18.2 (14) 0 (0) 15.0 (3) 33.3 (12) 11.1 (5) 0 (0) 16.5 (17) 
Person-years of follow-up§ 693.9 758.6 1200.0 -- 252.5 648.1 639.0 165.0 1452.5 
Overall Mortality Rate (95% 
CI) 
1441 
(775, 2678) 
922 
(440, 1936) 
1167 
(691, 
1970) 
-- 1188 
(383, 
3684) 
1852 
(976, 3026) 
782 
(326, 1879) 
-- 1170 
(727, 1883) 
Data are % (n) or means ± SD. 
†p<0.05; ‡p<0.01 
* - Denotes reference category 
§ Excludes non-Hispanic whites 
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Table 7: Cox Proportional Hazard by Age at Onset 
 Unadjusted Hazard 
Ratio 
95% CI 
p-value 
Continuous  
Age at Onset 1.2 (1.1-1.4) 0.01 
Categorical  
Age at Onset  0.01 
     <10 years* 1.00 -- 
     10-14 years 2.9 (0.5-15.8) 0.22 
     >14 years 9.1 (2.0-42.3) 0.01 
* - Denotes reference category; Variables made available for selection: sex (categorical), 
race (categorical), age at onset (categorical/continuous), and year of diagnosis 
(categorical/continuous).  
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Table 8: 20-year Mortality Rates (per 100,000 person-years) and Overall Standardized Mortality Ratios 
(SMRs) by Gender, Diagnosis Cohort, and Diagnosis Age in Non-Hispanic Blacks in the USVI and Allegheny 
County, PA (1965-1979) 
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4.7 FIGURES 
 
Figure 3: Life-Table Analysis by Sex (A), Race (B), Diagnosis Cohort (C), and Diagnosis Age(D) in the USVI 
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Figure 4: Life-Table Analysis Overall in Non-Hispanic Blacks in USVI  (1979-2005) vs. Allegheny County, PA 
(1965-1979) 
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5.1 ABSTRACT 
OBJECTIVE: The aims of this study were to compare the prevalence of type 1 diabetes 
complications (cardiovascular disease, nephropathy, and retinopathy) between non-Hispanic 
whites (NHW) and blacks (NHB) in a national sample and to evaluate the impact of modifiable 
risk factors and race on these outcomes. 
METHODS: Eighty individuals (60% NHW, 40% NHB) with type 1 diabetes were identified in 
the National Health and Nutrition Examination Survey (1999-2008) (determined as individuals 
diagnosed with diabetes less than age 30 and on continuous insulin therapy). Complication and 
risk factor status were determined based on self-reported responses on the questionnaire and 
relevant laboratory components. 
RESULTS: The prevalence of CVD did not differ by race group, and race was not associated 
with CVD after adjusting for risk factors. Univariately, the prevalence at > 20 years duration of 
both nephropathy and any retinopathy were significantly higher in NHBs (nephropathy: 48.6% 
vs. 18.4%, p=.01; retinopathy: 83.1% vs. 43.4%, p<.01). Furthermore, race was significantly 
associated with nephropathy [OR (95%CI): 1.18 (1.06, 1.30)] and retinopathy [OR (95%CI): 
1.20 (1.04, 1.36)] after adjusting for other risk factors(age, sex, diabetes duration, hypertension, 
hypercholesterolemia, glycemic control, and smoking).  
CONCLUSIONS: These data suggest that NHBs with type 1 diabetes are at increased risk of 
developing nephropathy and retinopathy, independent of well-established risk factors for these 
complications. The reasons for this disparity merit further investigation. 
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5.2 INTRODUCTION 
A decreasing incidence of type 1 diabetes complications, particularly nephropathy, retinopathy, 
and neuropathy, has been reported in the U.S. and globally over the past 30 years.47, 123, 124, 125 
Studies have also indicated that type 1 diabetes mortality rates are declining in the U.S.26, 105 
Increased access to treatment and improved disease management are likely major contributors to 
this decline in type 1 diabetes morbidity and mortality.108  However, mortality for African-
Americans with type 1 diabetes remains nearly 2.5 times higher than Caucasians.24, 25, 27, 28, 29  
The factors contributing to this disparity are unclear. There have been limited epidemiological 
studies investigating variations in the prevalence of major T1D complications among 
racial/ethnic groups, specifically African-Americans compared to Caucasians. A single report 
from the Allegheny County, PA population-based type 1 diabetes cohort showed that African-
Americans with type 1 diabetes were at significantly increased risk of developing end-stage renal 
disease (ESRD) at 20 years duration compared to Caucasians (21.9% vs. 5.2%).126  Existing type 
1 diabetes complications prospective cohort studies in the U.S. have very limited racial diversity, 
prohibiting any direct racial comparisons in the incidence of major complications and risk 
factors.44, 46 The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative survey which assesses the prevalence of a variety of health conditions, health 
behaviors and risk factors in adults and children in the U.S.127  Prevalence of diabetes 
complications has been previously reported in NHANES for individuals with type 2 diabetes and 
all diabetes (type 1 and type 2 combined); however, there has been no analysis exclusively in the 
type 1 diabetes population.39, 55, 128 While diagnosis of type 1 diabetes is not definitively collected 
as a diagnosed condition, other relevant factors (age of diagnosis and initiation/time of insulin 
therapy) are available to distinguish between type of diabetes; and has been used in previous 
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studies.129, 130, 131 NHANES is also racially diverse allowing for analysis stratified by race. We 
therefore investigated the prevalence of major type 1 diabetes complications (coronary artery 
disease, renal disease, and retinopathy) and risk factors (hypertension, hypercholesterolemia, and 
smoking) for NHWs compared to NHBs using data collected from NHANES for 1999-2008. 
Specifically, the objectives of this analysis were to: (1) assess racial differences in the prevalence 
of diabetes complications, (2) determine if racial differences exist in factors associated with 
development of diabetes complications, and (3) assess the impact of race, as a risk factor itself, 
on the development of diabetes complications. 
5.3 METHODS 
5.3.1 Study Population 
The National Health and Nutrition Examination Survey (NHANES), conducted by the National 
Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention, became a 
continuous survey in 1999, and data are released in 2-year increments. Datasets for 1999-2000, 
2001-2002, 2003-2004, 2005-2006, and 2007-2008 were combined. The NHANES 1999–2008 
comprised a nationally representative sample of the non-institutionalized civilian US adults and 
children. Each NHANES oversamples NHBs, Hispanics, or both. Health examinations including 
physical measurements and blood and urine collections are conducted in a mobile examination 
center. Survey instruments and physical and laboratory measurements have been described 
previously.132 The current study includes participants in NHANES 1999-2008, who underwent a 
health examination in the NHANES mobile examination center, and had available data for 
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diabetes diagnosis, age of diabetes diagnosis, insulin usage, and date of initiation of insulin 
usage. 
All NHANES protocols were approved by the NCHS Research ethics review board 
(previously known as the NHANES institutional review board); all participants provided written 
informed consent. 
5.3.2 Variable definitions 
Demographics 
Age, gender, race, and household income were all assessed by questionnaire. Race was self- 
classified as NHW and NHB; other and mixed racial groups were excluded for this study. 
Household income was categorized into $10,000 groupings up to $80,000 (i.e. $0-10,000, 
$10,001-20,000,…>$80,000). 
Diabetes Definition 
Type 1 diabetes for these analyses was defined as individuals diagnosed with diabetes less than 
age 30 and continuously on insulin therapy (initiation of insulin therapy within a year of 
diagnosis and current insulin use).  
Cardiovascular Disease (CVD) Definition 
CVD was defined as self-reported diagnosis of congestive heart failure (CHF), myocardial 
infarction (heart attack), coronary artery disease and/or angina. These CVD questions are only 
proctored to adults aged 20 and older. As such, for participants less than age 20, it was assumed 
that no clinical CVD was present. 
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Nephropathy Definition 
Nephropathy was defined as self-reported diagnosis of weak/failing kidneys (excluding kidney 
stones, bladder infections, or incontinence) or self-reported of receiving dialysis within the last 
12 months. 
Retinopathy Definition 
Retinopathy was defined as self-reported diagnosis of diabetes affecting the eyes or retinopathy. 
Glycemic Control Definition 
Glycemic control was assessed using HbA1C measures for each participant. The HbA1C 
measurements were taken using different laboratory methodologies over the study period. As 
such, the recommended correction equations were applied to the respective values. Poor 
glycemic control was defined as an HbA1C value less than 9.0%. This categorical term was used 
in logistic regression to further reduce any bias associated with the change in laboratory 
methodologies. 
Hypertension Definition 
Hypertension was defined as a mean resting blood pressure > 140/90 (either systolic >140, 
diastolic >90, or both), self-reported diagnosis of hypertension or use of hypertensive 
medication. Blood pressure was measured during the NHANES clinical examination. Three or 
more consecutive blood pressure measurements were taken (separated by 30 second breaks) after 
an initial 5 minutes of rest. The mean value was used in the analysis.  
Hypercholesterolemia Definition 
Hypercholesterolemia was defined as total cholesterol > 200 mg/dL, self-reported diagnosis of 
hypercholesterolemia or use of high cholesterol medication. Blood samples were collected 
during the clinical examination and later analyzed. Over the course of time, there were changes 
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in the instrumentation used to measure total cholesterol. Prior to 2006, total cholesterol was 
measured enzymatically in serum using the Roche Hitachi 717. In 2006, total cholesterol was 
measured enzymatically in serum using the Roche Hitachi 717 and 912. In 2007, total cholesterol 
was measured in serum using Roche Modular P chemistry analyzer. No adjustment of values was 
necessary to account for the change in instrumentation for total cholesterol between 2005-2006 
and 2007-2008.132  
Smoking Definition 
Smoking was defined as self-reported smoking > 100 cigarettes in lifetime.  
5.3.3 Statistical Analysis 
All statistical analysis incorporated recommended NHANES weights to account for non-
response bias and sampling methods.   Student’s t-test and one-way ANOVA were used to 
compare continuous variables between NHWs and NHBs. The χ2 (or Fisher’s exact) test was 
used to compare categorical variables between groups NHWs and NHBs. Prevalence of 
complications and risk factors were calculated in 10-year duration groups (1-10, 11-20, and  > 
20), stratified by race groups. Multivariate logistic regression was used to assess the impact of 
modifiable risk factors in NHWs and NHBs separately, adjusting for gender, age, and age of 
diabetes diagnosis. Univariate and multivariate logistic regression models were used to assess the 
impact of race on development of complications, adjusting for clinical (duration, and modifiable 
risk factors) and demographic (age at exam, gender, and household income) characteristics. 
Nephropathy was also included in the models as an independent variable when assessing CVD 
and retinopathy, because of its established association with both. Statistical significance was 
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considered as a p-value less than 0.05. Statistical analysis was performed using Statistical 
Analysis Software (SAS, Inc.). 
5.4 RESULTS 
There were 80 participants (48 NHW and 32 NHB) that met the previously described type 1 
diabetes definition in the 1999-2008 NHANES. Demographic and clinical characteristics of 
participants are shown by race in Table 9. NHBs were older with a mean age of diagnosis (18.9 ± 
1.7) compared to NHWs (15.1 ± 1.3) (p=.08) and a lower mean duration of diabetes (14.7 ± 2.3 
vs. 20.9 ± 2.7) (p=.08). NHBs had a higher mean body mass index and waist circumference (31.8  
± 2.1 kg/m2, 103.7  ± 4.9 cm) (p<.01). NHBs had a lower mean HDL, which trended towards 
significance (p=.07). Finally, NHBs had a significantly higher A/C ratio compared to NHWs 
(p=.02). 
Prevalence of major complications and risk factors by duration groups are shown in 
Figure 5. There were no prevalent cases of CVD in NHW or NHB with less than 20 years 
duration; however, at >20 years duration NHWs had marginally higher rates (17.4% vs. 11.9%) 
(p=.08). NHBs with >10 years duration had significantly higher rates of nephropathy compared 
to NHWs (11-20 years duration: 55.1% vs. 1.3% (p<.01), 21+ years duration: 48.6% vs. 18.4% 
(p<.01)). NHBs had higher rates of retinopathy at all durations compared to NHWs, with rates 
being nearly 2-fold higher at greater than 20 years duration (83.1% vs. 43.4%) (p=<.01). NHBs 
with less than 20 years duration had significantly higher rates of hypertension compared to 
NHWs (p<.01), with rates been virtually identical at >20 years duration (67.4% vs. 67.0%). 
Interestingly, 100% of NHBs with 11-20 years duration had hypertension. NHBs also had higher 
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rates of hypercholesterolemia at <20 years duration groups compared to NHWs (p<.01). Rates of 
ever smokers was highest in the >20 year duration group, with rates being significantly higher in 
NHWs compared to NHBs (70.5% vs. 37%) (p<.01). 
As shown in Table 10, NHWs with hypertension had 17% increased risk of CVD and 
34% increased risk of nephropathy; while NHBs with hypertension had 20% increased risk of 
CVD and 14% increased risk of nephropathy. Hypertension was not associated with retinopathy 
in either race group.  Hypercholesterolemia was associated with 15% and 20% increased risk of 
CVD in NHWs and NHBs, respectively. NHBs with hypercholesterolemia had 15% increased 
risk of nephropathy and 30% increased risk of retinopathy; however, hypercholesterolemia was 
not associated with either complication in NHWs. Glycemic control was not associated with 
CVD in NHWs or NHBs. However, glycemic control was associated with 30% and 40% 
increased risk of nephropathy in NHWs and NHBs, respectively. Glycemic control was 
associated with 17% increased risk of retinopathy in NHBs, no association was found in NHWs. 
Smoking was not associated with increased risk of CVD in either race group. Smoking was 
associated with a 8% increased risk of nephropathy in NHWs. Household income was 
significantly associated with CVD and retinopathy in NHBs, with 3% increase for every $10,000 
decrease in household income; however, this association was not seen in NHWs. NHWs with 
nephropathy had 96% increased risk of CVD, while NHBs with nephropathy had 28% increased 
risk of CVD and 20% increased risk of retinopathy. 
Race was univariately associated with CVD, nephropathy and retinopathy. (Table 11) 
NHBs were at decreased risk of CVD compared to NHWs (OR: .96 (.92, .99), p=.05); however, 
after adjusting for clinical characteristics and SES, there were no significant difference (OR: .92 
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(.81, 1.05)). NHBs had 18% increased risk of nephropathy and 20% increased risk of retinopathy 
compared to NHWs, even after adjusting for  clinical characteristics and SES. 
5.5 DISCUSSION 
This study evaluated racial differences in the prevalence of CVD, nephropathy, and retinopathy 
and factors associated with the development of each in a national sample with type 1 diabetes. 
The results of this analysis indicated that NHBs with type 1 diabetes have higher rates of 
nephropathy and retinopathy, even after adjusting for a variety of demographic and clinical 
characteristics. In contrast, univariately NHBs were at lower risk of CVD, which became non-
significant after adjusting for clinical characteristics, including diabetes duration, hypertension, 
hypercholesterolemia, and nephropathy, all of which were significant predictors of CVD. Similar 
risk factor associations with CVD were found in the Epidemiology of Diabetes Complications 
Study, a prospective cohort study of mostly NHWs, and the New Jersey 725 Study, a prospective 
cohort study of all NHBs.60, 62 Household income was associated with CVD in NHBs, but not 
NHWs. No measure of socioeconomic status (i.e. education level, household income, etc.) was 
included in the NJ725 study; however, a recent report from the EDC Study showed that SES was 
associated with incident CVD in type 1 diabetes.134  In addition, one might have predicted a 
higher prevalence of CVD in the NHBs because of the higher mean waist circumference and 
BMI and poorer lipid profile, but this was not the case. Of note, NHBs in this study had a lower 
mean HDLc, which trended toward significance (p=.07). Commonly, NHBs maintain higher 
rates of HDLc compared to NHWs, despite poorer cardiovascular risk profiles. No significant 
differences in HDLc were noted by sex; however, NHB women had a higher mean BMI and 
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waist circumference compared to NHB men. The lower HDLc in NHBs may result from a large 
proportion of NHB women with poorer lipid profiles due to multiple risk factors (i.e. high 
BMI/waist circumference, diabetes, hypertension, etc.). 
NHBs in this study had significantly higher rates of nephropathy. Similarly, a report from 
the Allegheny County, PA Registry Cohort showed that at 20-years duration NHBs had a nearly 
6-fold increased incidence of end-stage renal disease (ESRD) compared to NHWs.126  The 
researchers did not assess factors associated with the disparity in incidence, but other reports 
have shown that NHBs in the general population with and without diabetes have higher rates of 
both chronic kidney disease and ESRD.135, 136  Conversely, NHBs have been shown to have a 
45% lower case fatality (given chronic kidney disease) compared to NHWs, in the general 
population.137 It is possible the survival advantage of NHBs is contributing to the racial 
difference seen in this cross-sectional analysis.  
Similar to the NJ 725 study, glycemic control, hypertension and hypercholesterolemia 
were all significant predictors of nephropathy in NHBs, who had higher rates of hypertension 
and hypercholesterolemia at <20 years duration in this study.52  Yet, even after adjusting for 
these and other risk factors, NHBs remained at increased risk for nephropathy. Glycemic control 
has been previously shown to be a predictor of nephropathy.138, 139 The EDC Study indicated that 
individuals in lower SES groups have poorer glycemic control.135  While household income did 
not predict nephropathy in NHBs, the NHBs in this study had a higher proportion of individuals 
in the lowest SES category. This was the case in the SEARCH Study, where NHB youth had 
lower SES and poorer glycemic control, compared to NHW youth.17 Finally, there is some 
evidence which suggests that NHBs are genetically more susceptible to chronic kidney disease 
compared to other race groups.140   
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NHBs also had higher rates of retinopathy across all duration groups, compared to 
NHWs. Notably, the prevalence of retinopathy in NHWs in this study seems lower than what has 
been reported in other studies, particularly in the 11-20 year duration group.47, 141  The EDC 
Study estimated that nearly 25-39% of individuals with type 1 diabetes develop retinopathy by 
20 years duration, compared to 10% in this study.47 The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy, a long-term prospective study, found similarly high rates of diabetic 
retinopathy at 20 years duration (~47.5%) to the EDC Study.141 Both of these studies measured 
diabetic retinopathy in participants, compared to the self-reported data used in this analysis; this 
likely accounts for the lower rates found in this analysis. 
Another study using the NHANES, also showed that NHBs with and without diabetes 
have significantly higher rates of retinopathy compared to NHWs (Diabetes: 38.8% vs. 26.4%; 
US Population: 9.6% vs. 2.9%).39 Moreover, our findings are supported by a recent report from 
the SEARCH Study, indicating that minority youth with diabetes (including NHBs) are at 
increased risk of developing retinopathy, even after adjusting for diabetes duration and glycemic 
control.142  It is possible that retinopathy outcomes are improving in NHWs, but the drastically 
higher rates in NHBs warrant further exploration. 
In the NJ 725 Study of African-Americans with type 1 diabetes, diabetes duration, 
glycemic control, hypertension, and nephropathy were associated with the development and 
progression of retinopathy at baseline.48   Subsequent follow-up in the NJ 725, also found 
socioeconomic status, in addition to depression to be associated with retinopathy in NHBs.143  
Depression was not included in our analysis, but glycemic control and socioeconomic status 
were associated with risk of retinopathy in NHBs. It is possible that depression is contributing to 
the increased risk of retinopathy observed in NHBs.  
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The interpretations of the results of this study are subject to several important limitations. 
The criterion used to identify NHANES participants with type 1 diabetes, while it is the best 
method available, does not guarantee accurate distinction of diabetes type. While this method has 
been used in previous studies and is clinically relevant, it has not been formally validated and 
some subjects included in this analysis may not have type 1 diabetes. Yet, any bias resulting 
from diabetes misclassification is likely consistent across race groups. This is a cross-sectional 
study of data collected over a 10-year period, thus interpretation of prevalence rates and causal 
associations must be made with caution. While, NHANES encourages combining multiple years 
of data to increase power, it is possible that the prevalence of complications and risk factors is 
changing. Future studies should explore the racial differences, particularly in nephropathy and 
retinopathy, in a prospective study design to further understand the impact of race on type 1 
diabetes complication. Also, the complication status of individuals was largely based on self-
reported variables. Finally, even with use of a national sample, there is a small absolute sample 
size. This limitation is partly accounted for with the weighting methods used to adjust for the 
NHANES sampling design.  
In conclusion, this study indicated that despite improvements in diabetes management 
and care, NHBs have increased risk for complications, particularly nephropathy and retinopathy, 
compared to NHWs. Further research is needed to understand specific factors, both 
environmentally and genetically, associated with this increased risk. In addition, it appears that 
NHBs with type 1 diabetes may not maintain higher rates of HDLc, as has been commonly 
associated with NHBs. Finally, national surveys should consider revising existing protocols to 
more accurately identify patients with type 1 diabetes to expand research efforts in the 
prevalence of the disease and its complications. 
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5.6 TABLES 
Table 9: Demographic and Clinical Characteristics of NHANES Cohort with Type 1 Diabetes (1999-2008) 
 Non-Hispanic White 
NHANES 1999-
2008 
(n=48) 
Non-Hispanic 
Black 
NHANES 1999-
2008 
(n=32) 
p-value 
Demographics    
     Age, weighted mean (SD) 36.0 ± 2.4 33.6 ± 2.4  .50 
     Female sex, % (SE) 43.5 (9.7) 63.7 (8.5)  .14 
     Health insurance coverage, % (SE) 84.4 (5.9) 95.8 (4.1) .59 
Diabetes history, weighted mean (SD)    
     Age of diagnosis 15.1 ± 1.3 18.9 ± 1.7 .08 
     Duration 20.9 ± 2.7 14.7 ± 2.3 .08 
Physical measurements, weighted mean 
(SD) 
   
     Body mass index, kg/m2 24.2  ± 0.6 31.8  ± 2.1  <.01 
     Waist circumference, cm 85.4  ± 1.5 103.7  ± 4.9  <.01 
     Systolic blood Pressure , mmHg 114.7  ± 2.2 120.4  ± 2.7  .08 
     Diastolic blood Pressure, mmHg 65.6  ± 1.8 63.8  ± 2.8 .56 
Laboratory measurements, weighted mean 
(SD) 
   
     Non-fasting plasma glucose, mg/dL 248.5  ± 26.1 202.6  ± 45.0 .40 
     Hemoglobin A1C, % 8.6  ± 0.3 8.6 ± 0.5 .96 
     C-peptide, nmol/L 0.11 ± 0.04 0.17  ± 0.12 .80 
     Total cholesterol, mg/dL 184.8  ± 6.5 184.4 ± 7.8 .98 
     HDL cholesterol, mg/dL 61.0 ± 2.9 54.3 ± 2.2  .07 
     A/C Ratio, mg/mmol 23.8 ± 6.8 126.7 ± 43.3 .02 
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Table 10: Association between clinical and demographic variables and cardiovascular disease 
 Cardiovascular Disease 
 NHW (R2=.760) 
Odds Ratio (95% CI) 
NHB (R2=.481) 
Odds Ratio (95% CI) 
Age at Exam (per year) 1.00 (.99-1.01) 1.02 (1.00-1.04) † 
Gender   
     Male 1.00 (ref) 1.00 (ref) 
     Female .97 (.87-1.07) 1.01 (.90-1.13) 
Diabetes Duration (per 
year) 
1.00(.99-1.01) 1.01 (1.00-1.03) † 
Glycemic Control 1.15 (.95-1.35) 1.13 (.97-1.29) 
Hypertension 1.17 (1.01-1.33) † 1.40 (.85-1.98) 
High Cholesterol 1.15 (1.05-1.36) † 1.20 (1.05-1.36) † 
Smoking 1.12 (.97-1.30) .99 (.93-1.04) 
Nephropathy 1.96 (1.40-2.75) † 1.28 (1.13-1.44) † 
Household Income .99 (.97-1.02) .97 (.95-.99) † 
†- p<.05 
 
Table 11: Association between clinical and demographic variables and nephropathy 
 Nephropathy 
 NHW(R2=.412) 
Odds Ratio (95% CI) 
NHB (R2=.423) 
Odds Ratio (95% CI) 
Age at Exam (per year) 1.00 (.99-1.01) 1.02 (1.00-1.04) † 
Gender   
     Male 1.00 (ref) 1.00 (ref) 
     Female .97 (.86-1.07) 1.16 (.82-1.61) 
Diabetes Duration (per 
year) 
1.00 (.98-1.02) 1.00 (.98-1.02) 
Glycemic Control 1.30 (1.15-1.45) † 1.41 (1.23-1.59) † 
Hypertension 1.34 (1.12-1.66) † 1.14 (1.07-1.30) † 
High Cholesterol .86 (.67-1.07) 1.25 (1.04-1.46) † 
Smoking 1.08 (1.00-1.16) † .81 (.59-1.11) 
Household Income .98 (.96-1.01) 1.00 (.95-1.04) 
†- p<.05 
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Table 12: Association between clinical and demographic variables and retinopathy 
 Retinopathy 
 NHW (R2=.293) 
Odds Ratio (95% CI) 
NHB (R2=.493) 
Odds Ratio (95% CI) 
Age at Exam (per year) .98 (.96-1.00) 1.00 (.98-1.03) 
Gender   
     Male 1.00 (ref) 1.00 (ref) 
     Female 1.27 (1.10-1.43) † 1.12 (.83-1.52) 
Diabetes Duration (per 
year) 
1.03 (1.02-1.04) † 1.01 (.98-1.05) 
Glycemic Control 1.10 (.99-1.21) 1.13 (1.03-1.23) † 
Hypertension .74 (.47-1.15) .83 (.53-1.31) 
High Cholesterol .94 (.80-1.10) 1.03 (.94-1.12) 
Smoking 1.07 (.88-1.26) 1.17 (.76-1.47) 
Nephropathy 1.12 (.71-1.77) 1.30 (1.05-1.62) † 
Household Income .99 (.96-1.02) 1.03 (1.02-1.04) † 
†- p<.05 
 
Table 13: Association between race and cardiovascular disease, nephropathy, and retinopathy 
 
 
Model 1: Race 
(R2=.550) 
Model 2: Race +Clinical 
Variables1 
(R2=.512) 
Model 3: Race + 
Clinical Variables + 
SES2 
(R2=.523)
 
CVD    
     NHW 1.00  1.00 1.00 
     NHB .96 (.92-.99) † .93 (.90-1.33) .92 (.81, 1.05) 
Nephropathy    
     NHW 1.00  1.00 1.00 
     NHB 1.22 (1.11-1.36) † 1.20 (1.08-1.32) † 1.18 (1.06, 1.30) † 
Retinopathy    
     NHW 1.00  1.00 1.00 
     NHB 1.42 (1.26-1.61) † 1.26 (1.09-1.44) † 1.20 (1.04, 1.36) †  
†- p<.05    
Model 1= Race 
Model 2= Race + Age + Gender + Duration + Hypertension + High Cholesterol + Glycemic Control + Smoking Status + 
Nephropathy 
Model 3= Race + Age + Gender + Duration + Hypertension + High Cholesterol + Glycemic Control + Smoking Status + 
Nephropathy + Household Income 
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5.7 FIGURES 
 
Figure 5: Cross-Sectional Prevalence of Complications and Risk Factors by Race and Duration 
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6.0  DISCUSSION 
6.1 SUMMARY OF FINDINGS 
The objective of this study was to evaluate the impact (incidence, morbidity and mortality) of 
type 1 diabetes on African-Americans (including, those of Caribbean-descent), largely focused 
on the U.S. Virgin Islands, a majority non-Hispanic black population. While the USVI differs 
geographically and culturally from the contiguous U.S., these results indicate that the impact of 
type 1 diabetes on African-Americans is comparable to the general U.S. population. The 
incidence of type 1 diabetes is steadily increasing in African-Americans in the USVI, with 
unexplained epidemic-like increases occurring throughout the past 30 years. African-American 
boys seem to lack the well-established pubertal rise in incidence, which is seen in African-
American girls and other race youth. This study, for the first time, reported all-cause mortality in 
T1D in the USVI. African-Americans in the USVI have high type 1 diabetes mortality rates as 
seen in African-Americans in Allegheny County, PA, and other US-based studies. 24, 26, 28, 105  
This study indicated that individuals diagnosed with type 1 diabetes after puberty were at nearly 
9 times greater risk of death compared to individuals diagnosed before puberty (Cox 
Proportional Hazard: 9.1 (95% CI 2.0, 42.3). In addition, African-Americans in the USVI with 
type 1 diabetes die at a rate nearly 6 times higher than the general population (SMR: 5.8 (95% CI 
2.7, 8.8). 
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This study also investigated racial differences in the prevalence of type 1 diabetes 
complications in a national sample, to further explore the etiology of the disparity observed in 
overall mortality. The results showed that AAs with T1D had significantly higher rates of 
nephropathy and retinopathy, but borderline lower rates of CVD, compared to Caucasians. AAs 
with T1D also had higher rates of hypertension and hypercholesterolemia, both known risk 
factors for type 1 diabetes complications. After adjusting for demographic and clinical 
characteristics and risk factors, AAs remained at increased risk of having nephropathy and 
retinopathy. These data suggest that factors, either environmental or genetic, other than the 
traditional risk factors for complications, may play a critical role in the development of 
complications in AAs. Further research efforts are needed to identify these factors. 
6.2 INCIDENCE OF DIABETES IN AFRICAN-AMERICAN YOUTH 
This study assessed modern trends in incidence of diabetes, both type 1 and type 2, among youth 
in the USVI. While the sample size was small, some very important epidemiologic outcomes 
were observed and must be considered. The first is the unexplained increasing incidence of type 
1 diabetes in African-American youth. Historically, African-American youth have maintained 
significantly lower rates of type 1 diabetes.99 Early reports in the USVI indicated that Caucasians 
(28.9/100,000) had nearly 5-times increased risk compared to African-Americans (5.9/100,000).  
Based on this present analysis, this racial divide has virtually disappeared, with overall incidence 
rates in African-Americans (21.4/100,000) being comparable to Caucasians (24.7/100,000) in 
years 2006-2010. A similar story has been shown across other studies in the U.S.94 In the 1980s, 
an early report from Southern California indicated that Caucasians (28.6/100,000) had a 2.9 –
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fold increased risk of developing type 1 diabetes compared to African-Americans (9.9/100,000) 
in the same community. A subsequent report from Allegheny County, PA showed a reduced 
racial disparity, with Caucasians being at 1.5-times greater risk of having type 1 diabetes 
compared to African-Americans.144 Furthermore, contemporary studies have found little to no 
racial disparity. The SEARCH for Diabetes in Youth Study, found a small racial gap in incidence 
for Caucasians (47.5/ 100,000) and African-Americans (28.3/100,000), with only a 0.6-fold 
difference. The increasing incidence of type 1 diabetes in African-Americans may be explained 
by a combination of genetic and environmental factors, but little effort has been made to 
specifically elucidate causes in African-Americans. This is largely because the overall etiology 
of type 1 diabetes remains unclear. It is difficult to investigate changes in subgroups, when 
research has not clearly identified overall causes. However, greater increases in ethnic minority 
groups, are likely major contributors to the persistent increase in worldwide incidence. There are 
a variety of suspected environmental and genetic causes involved in the etiology of type 1 
diabetes, many of which are currently being investigated, including, viral infections, dietary 
exposures, maternal risk factors, and immunizations.144, 145 Multiple genes have been shown to 
play some role in the development of type 1 diabetes, but genetic epidemiology studies have not 
focused on racial differences in these studies.147 Yet, if there is some genetic difference by race, 
it is possible that the increase of racial admixture is in part contributing to the rise in incidence. 
Future studies may consider evaluating the incidence of type 1 diabetes in various subgroups of 
African-Americans (i.e. based on percentage of racial admixture).  
A recent study also indicated that an increased humoral autoimmune response (antibody 
response produced by B cells) to islet antigens may be contributing to the increasing 
incidence.148 While additional efforts are needed to understand the environmental and/or lifestyle 
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factors that result in the intensified autoimmune response, there may be some link with the 
commonly discussed association of type 1 diabetes and concomitant infections. In an effort to 
explain the epidemic like –increases in incidence that have been observed in various 
populations149, researchers have focused some attention on the co-occurrence of “outbreaks” of 
viral infections, such as varicella and Dengue fever, suggesting that the immune system response 
initiated by these conditions is associated the onset of type 1 diabetes in youth. There were no 
data collected on viral infections in this study, but future registry follow-up may consider adding 
recent infections to the data collection form.  
In addition, obesity has been suspected as a contributor to type 1 diabetes in youth.150 
This study indicated that the proportion of youth with type 1 diabetes that are overweight at 
diagnosis has increased. In earlier studies in the USVI, the majority of youth diagnosed with type 
1 diabetes were underweight. A U.K.-based study also found that a higher BMI in childhood was 
an independent risk factor for type 1 diabetes.145 However, consistent with findings from the 
SEARCH Study15, another study in the U.K. found no association between BMI and type 1 
diabetes.151 In contrast, obesity was associated with type 2 diabetes in both studies and is clearly 
contributing to the rapidly increasing incidence of type 2 diabetes observed in the USVI and 
worldwide. Efforts to combat obesity and delay the progression of type 2 diabetes in youth must 
remain a primary public health objective. 
A final consideration for the increasing incidence of type 1 diabetes is the impact of 
socioeconomic status. In our study, limited information was available on socioeconomic status, 
aside from insurance coverage. African-Americans had a significantly higher proportion of youth 
uninsured and publicly insured compared to other races, indicative of lower socioeconomic 
status. Interestingly, the relationship of type 1 diabetes and socioeconomic status does not seem 
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to be disadvantageous to those at lower socioeconomic conditions. The SEARCH Study showed 
that youth with type 1 diabetes were more likely to live in more affluent communities, with 
higher occupation and education levels.152 The opposite relationship has been associated with 
type 2 diabetes in youth.151 As such, socioeconomic status may certainly be contributing to the 
increase in type 2 diabetes observed in the USVI, but it is less likely to be a factor contributing to 
the increase in type 1 diabetes incidence. 
The other major finding of this study relevant to type 1 diabetes incidence was the 
missing pubertal rise in incidence in African-American boys. As previously discussed, this 
finding was shown, but not highlighted, in previous assessments in the USVI and other 
population-based studies in the US, including the SEARCH Study (Figure 6).5  There were no 
apparent differences in characteristics between African-American boys and girls in this study or 
the SEARCH Study.17 In the SEARCH Study, a greater proportion of African-American boys 
were underweight at diagnosis compared to girls; however, this difference occurred across all 
age groups, suggesting that obesity is likely not a factor in the missing pubertal rise in boys. 
After a thorough review of literature, no major hormonal differences in African-Americans boys 
compared to boys of other races were identified. However, African-Americans boys were found 
to have secondary sexual characteristics (i.e. pubic hair) at higher frequencies at earlier ages, 
compared to Caucasian boys.153 While this may be indicative of an earlier initiation of pubertal 
processes in African-American boys, it would not negate the traditional pubertal age ranges. One 
may even argue that this early puberty would then likely increase rates in pre-pubertal African-
American boys, which is not the case. However, if obesity, which is more prevalent in girls than 
boys, is contributing to the increased incidence of type 1 diabetes, this would result in lower 
overall rates in boys. The combined effect of the two causative associations may contribute to the 
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“missing” pubertal rise in incidence. Nonetheless, this phenomenon in African-American boys 
merits further exploration. Research efforts to determine the etiology of type 1 diabetes should 
include specific analysis in pubertal African-American boys. 
 
Figure 6: Incidence Rates of Type 1 Diabetes among Non-Hispanic Blacks by Age and Sex in the SEARCH 
and USVI Cohorts 
6.3 TYPE 1 DIABETES MORTALITY IN AFRICAN-AMERICANS 
This study also investigated type 1 diabetes mortality in African-Americans in the USVI using 
individuals registered in the Childhood Diabetes Registry during 1979-2005. While the study 
included all races, reflective of the general population, there were few cases of Caucasians (n=6) 
and Hispanics (n=20) in the cohort, and no deaths in Caucasians. This is the first ever mortality 
follow-up of type 1 diabetes in Hispanics. The overall mortality in Hispanics [1188 per 100,000 
person years (95%CI 383, 3684)] was similar to African-Americas [1167 per 100,00 person 
years (95% CI 691, 1970)] in the USVI. Of greatest interest was mortality in African-Americans. 
There were no significant differences by race (African-Americans vs. Hispanics), sex, or 
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diagnosis year groups; however, there was a significant difference by age at onset groups. 
Individuals diagnosed post-puberty (>14) had significantly poorer survival than those diagnosed 
pre-puberty (<10) and during puberty (10-14). This finding was also observed in the Allegheny 
County, PA Registry cohort mortality follow-up, but not so dramatically. It has be postulated that 
the early years (pre-puberty) of type 1 diabetes are associated with minimal damage aside from 
acute complications and have a small impact on long term outcomes. In addition, it is possible 
that youth diagnosed later in adolescence are less likely to be compliant with recommended 
diabetes management and the lack of self-management during adolescent years may cause lasting 
damage and impact long term disease management. In the USVI, this phenomenon is likely 
further complicated by the limited health services available to youth with type 1 diabetes. As is 
likely the case in the contiguous U.S., education systems are not tailored to the specific needs of 
youth with chronic illnesses, particularly those that require daily management. In the USVI, 
many secondary schools have only one (or even no) school nurse, who is tasked with managing a 
large number of students. Thus, the youth are often on their own with maintaining their daily 
regimens, which often include at least three daily visits to the nurses’ office to check blood 
glucose and/or administer insulin. This process is not only disruptive to the education process, 
but it can also be socially isolating for adolescents, which may encourage rebellion.   
Many studies have reported worse type 1 diabetes mortality for African-Americans, 
compared to Caucasians.24, 25, 26, 28, 105 As mentioned, there were no deaths in Caucasians in the 
USVI so a direct comparison could not be made; however, African-Americans in the USVI had 
significantly higher mortality compared to Caucasians in the Allegheny County, PA Registry 
cohort. Consequently, there were no significant differences in mortality or survival between 
African-Americans in the two cohorts. There has been a limited investigation into the exact 
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causes of the higher mortality seen in African-Americans. One possible mechanism is increased 
chronic complications. Though not a central focus of this study, all deaths (n=14), except one,  in 
African Americans were due to chronic complications; the other death was due to acute 
complications. A similar pattern was observed in Allegheny County, PA. In contrast, in 
Caucasians in Allegheny County, PA, 16.7% of deaths were due to non-diabetes related causes, 
including accidents and cancer. Further understanding of type 1 diabetes complications in 
African-Americans may explain this disparity. 
Also of interest, African-Americans in the USVI (SMR: 5.8 (95% CI 2.7, 8.8)) have 
comparable SMRs to African-Americans in Allegheny County, PA (SMR: 7.5 (95%CI 5.2, 9.8)) 
. Consequently, African-Americans in Allegheny County, PA also have similar SMRs compared 
to Caucasians in Allegheny County, PA (SMR: 7.5 (95% CI 6.3, 8.5)) . This paradox, of 
drastically higher mortality rates and comparable SMRs, remains unexplained. It is possible that 
similar factors contributing to increased background mortality are also contributing to the 
increased type 1 diabetes mortality in African-Americans; for example, increased risk of 
hypertension, chronic kidney disease, and coronary heart disease. Of note, there were no deaths 
due to accidents/violent crimes in either African-American cohort. The long term lifestyle 
modifications of patients with type 1 diabetes may impact their socialization and in fact protect 
them from risky behaviors that would lead to vulnerability to violent acts. In addition to further 
exploration of type 1 diabetes complications and risk factors in African-Americans, analysis of 
lifestyle factors may provide additional insight on the increased rates of type 1 diabetes 
mortality. 
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6.4 TYPE 1 DIABETES COMPLICATIONS IN AFRICAN-AMERICANS 
Apart from mortality data, there are few data available exploring racial differences in type 1 
diabetes complications. This type of analysis is critical, particularly in understanding the results 
of mortality studies and developing targeted approaches for reducing the morbidity of type 1 
diabetes in African-Americans. The major finding of this study is that race appears to be 
associated with development of diabetic nephropathy and retinopathy, but not CVD. Glycemic 
control has been independently associated with nephropathy and retinopathy in both Caucasians 
and African-Americans with type 1 diabetes in the EDC Study and the NJ 725 Study.52, 48, 138 
Notably, significant racial differences have been observed in glycemic control. In the SEARCH 
Study, African-American youth had significantly higher HbA1C values at diagnosis, compared 
to Caucasian youth. A study, using NHANES data, demonstrated that African-Americans adults 
(36.9%) with diabetes were less likely to achieve optimal glycemic control compared to 
Caucasians (48.6%).154   
A recent study using NHANES data indicated that nationwide rates of diabetic 
nephropathy are increasing.130 It is not surprising that race significantly predicted nephropathy as 
African-Americans without diabetes are at increased risk for developing chronic kidney disease 
compared to Caucasians.116 However, no direct comparison was made with the general 
population without diabetes. Future analysis may consider evaluating if the impact of race on 
nephropathy is greater in the type 1 diabetes population compared to the general population. In a 
multi-center study in the U.S. African-Americans with diabetes had 2.6-fold greater risk of 
microalbuminuria, compared to Caucasians.136 Understanding the risk factors for developing 
nephropathy in African-Americans is critical. Researchers have postulated that African-
Americans are genetically more susceptible to chronic kidney disease, through various genetic 
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pathways.140 One report hypothesized that the over-expression or activation of a transform 
growth factor-beta (TGF-beta) signaling pathways may be contributing to the higher risk for 
various health conditions, including hypertension and ESRD, in African-Americans. Genetic 
studies have shown that African-Americans have a higher frequency of a specific mutation that 
may predispose them to TGF-beta over-expression and thereby increased disease risk.155 The 
disparity seen in nephropathy may also be partially accounted for by African-Americans’ 
increased risk for hypertension. 
In previous studies, African-Americans have been shown to have higher rates of 
retinopathy compared to Caucasians, in cohorts with both type 1 and type 2 diabetes156, 157, 158 
and type 1 diabetes alone49, 159, including a recent follow-up report from the SEARCH Study.142 
The NJ 725 Study, which was designed specifically to assess risk factors for retinopathy has 
reported that diabetes duration, glycemic control, age, and hypertension are associated with 
retinopathy in African-Americans, similar to the findings in this study.48 As with nephropathy 
there is also some evidence that supports that genetics may play a role in development of diabetic 
retinopathy.159  
Moreover, the results of this analysis indicate that factors other than the traditional risk 
factors are contributing to development of complications in African-Americans. One such risk 
factor is depression. The NJ 725 study demonstrated that depression was a risk factor for poor 
glycemic control, retinopathy, and nephropathy in African-Americans.143 Individuals with 
depressive symptoms were nearly 2.5-times more like to develop retinopathy and 3.0-times more 
likely to develop nephropathy.48, 143 The SEARCH Study found that African-American youth 
with diabetes were significantly more likely to have depressive symptoms compared to 
Caucasian youth.160 Also, associated with depression and possibly with the increased risk of 
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complications in African-Americans is socioeconomic status. While household income was 
included in this analysis, future analysis may consider including a more comprehensive 
definition of socioeconomic status that accounts for geographic location, education level, and 
employment status. The EDC Study clearly demonstrated that lower socioeconomic status was 
associated with poorer glycemic control, which may the pathway to developing complications.  
Of note, HbA1C was the primary indicator of glycemic control and individual diabetes 
management. While this is a relevant variable, it does not completely account for an individuals’ 
diabetes management, particularly over a long period of time. Glycemic control combined with 
other variables, such as health care utilization and number of hospitalizations, would likely 
provide a more accurate account of individual diabetes management. These variables may 
possibly account for some of the racial differences in complications observed in this study.  
A final consideration of these results is the poorer lipid profile observed in NHBs 
compared to NHWs.  Despite similar mean total cholesterol, the mean HDL was lower for NHBs 
compared to NHWs. When stratified by sex, there were no differences between NHB males and 
females, as shown in Table 14 (below). When compared to the mean HDL of comparable age 
groups from the Lipids Research Clinics Program Prevalence Study161 and the Bogalosa Heart 
Study162, NHW males and females appear to have a higher mean HDL and NHB males and 
females have a comparable mean HDL. (Table 14) This suggests that NHWs with type 1 diabetes 
may have improved lipid profiles, compared to the general population; however, this advantage 
is not seen in NHBs. This difference may be associated with access and utilization of care. 
Patients with type 1 diabetes, likely have more contact with health care professionals for routine 
care. This may increase their likelihood of screening for co-morbid conditions as well as 
preventive care, such as statin therapy to reduce cholesterol. Though there were no race 
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differences observed in the overall use of such anti-cholesterol medications, there may be a 
difference in the time at which these therapies were initiated (prevention vs. treatment). This 
would support the hypothesis that NHBs have lower access to and utilization of the necessary 
health services, as a contributing factor to higher rates of complications. 
 
Table 14: Mean HDL and Total Cholesterol for by race and sex in the NHANES T1D Sample, EDC Study (at 
baseline), LRC Prevalence Study, and Bogalusa Heart Study 
 
In summary, the results of this study show racial differences in risk for nephropathy and 
retinopathy in type 1 diabetes. This increased risk is likely explained by a combination of 
increased genetic susceptibility, resulting in increased metabolic risk, and contributions of 
environmental factors, including socioeconomic status. While retinopathy is less commonly 
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associated with mortality, the increased risk of nephropathy in African-Americans with type 1 
diabetes is likely a contributor to the consistently reported increased mortality.    
There are some common implications of these studies. First, collectively these analyses, 
despite small sample sizes, suggest that African-Americans have increased morbidity and 
mortality due to type 1 diabetes compared to Caucasians. The increased risk of complications, as 
indicated by the NHANES analysis, is likely contributing to the increased risk of premature 
mortality, shown in this and previous mortality studies including African-Americans. In the 
mortality follow-up, 70.6% of deaths involved end-stage renal disease as a primary, contributing, 
or underlying cause of death. This is consistent with the increased risk of nephropathy in 
African-Americans found in the NHANES study. The increased morbidity and mortality coupled 
with the rising incidence of type 1 diabetes shown in the registry follow-up, depicts a progressing 
health disparity for African-Americans. Secondly, the similarities noted across these studies 
suggest that African-Americans experience similar disparate burden of type 1 diabetes across 
different geographic locations. This implication is supported by the similar incidence rates for 
non-Hispanic blacks in the USVI and other cohorts in the US, the comparable mortality 
experience in the USVI and Allegheny County, PA cohorts, and the confirmed rates of 
complications in the NHANES study compared to other cohort studies. This consideration is 
important for interpreting future epidemiologic investigations exploring racial differences in the 
burden of type 1 diabetes.  
In addition, these studies strongly suggest that conventional knowledge of the natural 
history of type 1 diabetes may not fully account for the burden of the disease in African-
Americans, including incidence patterns and risk factors for complications. Furthermore, these 
analyses confirmed findings related to the natural history of type 1 diabetes from previous U.S-
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based studies.. This implication is particularly important in generalizing results from existing 
prospective cohort studies, both the EDC Study and the New Jersey 725 Study, which only 
reflect small geographic areas.  
Finally, the individual analyses are handicapped by small sample sizes. In public health 
research, large samples are not always available and commonly not available for rare conditions 
or diseases. The results abstracted from these analyses provide an example of the significance of 
studying small populations, despite difficulties in detecting small differences, and the types of 
implications that can be made for larger populations and developing future research priorities. 
Various statistical methods to account for small sample sizes were used in each of these analyses, 
namely Fischer’s exact test for categorical comparisons and the Poisson distribution for 
hypothesis testing. 
6.5 STRENGTHS AND WEAKNESSES 
This study has several strengths that should be noted. The study provides contemporary insights 
on the burden of type 1 diabetes in the USVI. The registry update had 96.7% case ascertainment, 
estimated using the well-established capture-recapture method. The mortality follow-up, which 
confirmed vital status of 91% of cases in population-based registry, is the first in this minority 
population and in the entire Caribbean region. This study serves as a foundation for investigating 
temporal trends in mortality in the territory. In addition, data from a nationally representative 
survey, with standardized methods, was used to investigate the impact of race on type 1 diabetes 
complications. 
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The primary weakness of this study is the small sample sizes in each of the individual 
analyses. The general population in the USVI is small and not ideal for epidemiological 
investigations of rare conditions; however, this does not negate the public health significance of 
understanding these conditions in this and other small populations. As indicated by this study, 
these studies can provide insight relevant to larger populations. In addition, the absolute number 
(n=80) of cases in the NHANES analysis was small; our power to detect differences was 
strengthened by the weighted adjustments for the sampling methods. In addition, as previously 
discussed, the NHANES analysis was limited by the exclusion of glycemic control as a risk 
factor for complications.  
6.6 FUTURE RESEARCH 
While this study has addressed the outlined objectives, there are several research questions that 
remain unanswered. First, additional research is needed to understand the environmental factors 
that contribute to the epidemic-like increases in type 1 diabetes incidence. To further explore the 
concomitant disease hypothesis, researchers may combine data from this study with incident data 
of varicella (Chicken Pox) and Dengue Fever in youth. Also, information about exposure to these 
conditions may be added to data collection for future registry updates. Secondly, the missing 
pubertal rise in African-American boys should be investigated further. The SEARCH Study may 
be an ideal place to expand this investigation as they have collected extensive demographic and 
clinical data on study participants.  
The impact of race on type 1 diabetes complications also remains unclear. While there 
are obvious differences in mortality and prevalence of complications, the factors associated with 
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these differences need further epidemiologic investigation. A longitudinal prospective cohort 
study with a sufficient sample of African-Americans is of course the ideal method. However, 
combining individual level data from the Epidemiology of Diabetes Complications Study and the 
New Jersey 725 Study is a logical next step to establish clear research questions and hypotheses 
for a large cohort study. Finally, national surveys, including NHANES, National Health 
Interview Survey, and the Behavioral Risk Factor Surveillance System, should modify current 
questionnaires to clearly distinguish between types of diabetes. This will allow further 
exploration of frequency, distribution and determinants of type 1 diabetes and its complications 
in the nation. This would also allow continuous monitoring for temporal improvements. 
6.7 PUBLIC HEALTH IMPLICATIONS 
Despite significant advances in diabetes care, management, and outcomes in recent decades, 
African-Americans remain at increased risk of mortality and based on the results of this study, 
complications. The current study adds significantly to the knowledge of contemporary trends of 
type 1 diabetes incidence in ethnic/minorities. Ongoing efforts to monitor the increasing 
incidence must continue in the USVI and the contiguous US. The study, for the first time, 
assessed the morbidity of type 1 diabetes in the USVI. Historically, rates of type 1 diabetes in the 
territory have remained lower than the contiguous US, but this study has shown a dramatic 
increase over the past decade. This increase is of great public health significance, as the current 
health care infrastructure in the USVI is not designed to manage a large population of youth with 
diabetes. The results of this study should be used to support efforts to increase access to medical 
specialty and diabetes supportive services for youth in the territory; particularly, with the 
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apparent disproportionate impact of type 1 diabetes on African-Americans. Additional efforts to 
provide intensive care to high-risk African-American youth may be a possible approach to 
reducing the gap in complications and mortality. There are few studies evaluating racial 
differences in type 1 diabetes complications, but this study emphasizes the necessity for 
additional research to understand the factors contributing to poorer outcomes in African-
Americans. Most studies have focused on racial differences in diabetes complications in cohorts 
with type 2 diabetes, but the etiological differences and management of type 1 and type 2 
warrant separate analysis. 
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Abstract 
Self-reported data on the epidemiology of T1D complications has not been extensively 
validated. The repeatability and validity of a 5-page survey, developed to collect self-reported 
data on physician-diagnosed diabetes complications, treatment, health-care utilization and 
demographic factors for randomly selected participants in the Allegheny County, PA T1D 
Registry were therefore evaluated. The characteristics of those discordant on the basis of 
agreement of repeated surveys (n=30) approximately 1 year apart for participants or for validity, 
the survey responses of 30 participants who were examined 2-3 years earlier. Kappa statistics (k) 
were calculated to determine agreement between repeated surveys and between the survey and 
clinical exam. High reliability agreement (k>.60) was observed for all complications and risk 
factors, except stroke (k=.03) and peripheral vascular disease (k=.46), both of which had a low 
overall prevalence, in the repeated surveys. A high level of agreement was also observed in the 
validation with clinical exam data, with lesser agreement (.40<k<.60) being shown for overt 
nephropathy (k=.46) and high triglycerides (k=.52). In the repeatability sample, individuals 
discordant for at least one complication appeared less likely to check blood glucose regularly 
(p=.160). In the validity sample, discordant cases were significantly less likely to have seen a 
physician in the last year for routine care of diabetes (p=.02) and, though statistically non-
significant, were twice as likely to be male (p=.12) and less likely to check their blood glucose 
3+ times daily (p=.10). There were no differences by concordance for mean age, diabetes 
duration, or HbA1c. Though the results of this analysis show high repeatability and validity and 
little bias of self-reporting of complications and risk factors among patients with T1D, less 
frequent physician follow up was associated with invalid survey responses. 
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Introduction  
Patients with Type 1 diabetes often experience microvascular and macrovascular 
complications throughout their lives. Researchers investigating the epidemiology of these 
complications and risk factors often rely on self-reported data to ascertain incidence and 
prevalence.44, 163 Validation studies in other populations have shown self-reported data to be an 
accurate tool for assessing prevalence of disease, but results are inconsistent for assessing 
incidence of disease.164, 165, 166, 167, 168 In addition, previous studies evaluating the reliability and 
validity of self-reported data have demonstrated variability in the accuracy of patient reporting, 
based on the disease or condition.169, 170, 171, 172, 173  
The Diabetes Epidemiology Research International Study, is a multi-centered population-
based study of the incidence of Type 1 diabetes in 50 countries. The Allegheny County, PA 
center recently reported 30-year all-cause mortality.29 As a part of this follow-up, researchers 
developed a brief questionnaire to assess the prevalence of complications in the population. The 
reliability and validity of this questionnaire is uncertain. The objective of this study was to 
evaluate the reliability and validity of this self-administered questionnaire through agreement of 
repeated surveys and clinical exams. 
Methods 
Survey development 
A 5-page survey was developed to collect self-report data on physician-diagnosed 
diabetes complications, common diabetes treatments, health-care utilization, and demographic 
and socioeconomic factors for participants in the Allegheny County, PA Type 1 Diabetes 
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Registry.  This survey was created based on surveys developed and validated for the Pittsburgh 
Epidemiology of Diabetes Complications (EDC) Study. 44  
Study population 
The Allegheny County, PA Type 1 Diabetes Registry cohort (n=1,075) comprised all 
individuals diagnosed in Allegheny County, PA with childhood-onset (age<18 years) type 1 
diabetes between 1 January 1965 and 31 December 1979, and placed on insulin at diagnosis. 
Ascertainment levels exceeded 95%.29 Individuals with diabetes from a secondary cause (i.e., 
cystic fibrosis, Down’s syndrome, or steroid-induced diabetes) were excluded. 
To determine vital status as of 1 January 2008, all participants were mailed an Allegheny 
County, PA Type 1 Diabetes Registry survey and consent form.  Individuals who failed to 
respond to mailings were contacted by telephone.  The study protocol was approved by the 
University of Pittsburgh Institutional Review Board. 
Data collection 
To assess the reproducibility of the survey, we randomly selected 30 respondents, and 
mailed the same survey approximately one year after their initial response.  We compared the 
responses between the two surveys. 
To validate the self-report data in this study, we selected 30 Allegheny County, PA Type 
1 Diabetes Registry participants who were also participants in the Pittsburgh EDC Study.  Based 
on the18-year follow-up EDC examination data, an Allegheny County, PA Type 1 Diabetes 
Registry survey was completed.75  This was then compared to the self-reported survey responses 
to determine the proportion of concordance. Incident cases of complications/risk factors were 
removed from all analyses for each complication/risk factor independently. 
Statistical Analysis 
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Kappa statistics and their 95% confidence intervals were calculated to determine 
agreement between repeated surveys and the initial survey and the survey produced from exam 
results. Scores of 0.0-0.4 correspond to a low agreement; 0.4-0.6 , intermediate agreement; 0.6-
0.8, high agreement; and 0.8-1.0, very high agreement. All statistical analysis was conducted 
using SPSS statistical software. 
Results 
The results of the repeatability analysis are shown in Table 1. Very high agreement was 
observed for coronary heart disease (k=.82), retinopathy (k=.80), neuropathy (k=.91), 
nephropathy (k=.87), hypertension (k=.93), high cholesterol (k=.80), high triglycerides (k=.84), 
current and ever smoking (k=1.00), and cataract (k=.86). High agreement was observed for 
glaucoma (k=.78). Low agreement was observed for both stroke (k=.03) and peripheral vascular 
disease (k=.46), both of which had very low prevalence in the sample. 
The results of the validity analysis are shown in Table 2. Similar to the repeatability 
results, very high agreement was observed for proliferative retinopathy (k=.92) and hypertension 
(k=.91). High agreement was observed for neuropathy (k=.67), any proteinuria (k=.62), and high 
cholesterol (k=.73) and intermediate agreement was observed for overt nephropathy (k=.46) and 
high triglycerides (k=.53). Again, where very low prevalence of the health condition occurred, 
poor agreement was observed, as shown with peripheral vascular disease. 
Characteristics of participants by reporting behavior and complication/risk factor status 
for the repeatability and validity samples are shown in Tables 3 and 4. There were no significant 
differences in characteristics between individuals with consistent reporting compared to those 
that reported discordantly in the repeatability sample. However, in the validity sample, 
concordant cases were more likely to have seen a physician with the past year for routine care of 
103 
 
diabetes (100%) compared to discordant cases (71.4%) (p=.02). Also, discordant cases were 
more likely to be uninsured (7.1%) compared to concordant cases with complications (0%) 
(p=.03). 
Discussion 
 
This analysis demonstrated the repeatability and validity of self-reported data collected via a 
self-administered questionnaire to patients with type 1 diabetes. Overall, repeatability was high 
for all complications and risk factors, except stroke and peripheral vascular disease. Of note, 
both of these conditions had a low overall prevalence in the sample population. This finding may 
be less associated with specific conditions, and more broadly suggests that self-reported data of 
low occurring conditions is less reliable. Similarly, the validity of the complications and risk 
factors was high for all conditions except overt nephropathy, which had a low overall prevalence. 
As overt nephropathy may or may not be symptomatic, it is possible that the case that was not 
confirmed had not been formally diagnosed; however, all study patients (and respective 
physicians) are notified of study results. Furthermore, these results also indicated that individuals 
who self-reported invalidated responses were more likely to not have seen a physician for routine 
care within the last year. Consequently, a higher percentage of individuals who self-reported 
invalidated responses were more likely to be uninsured, which is likely a factor in the decreased 
proportion receiving routing diabetes care. The primary limitation of this study is the small 
sample size. In addition, the validity analysis is limited in that the examinations occurred prior to 
the self-administered questionnaire, and there may be some impact of time, though conditions 
developed during the lapsed time were not included. In conclusion, these results provide useful 
insights into the reliability of self-reported responses in long-term follow-up studies of 
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individuals with type 1 diabetes and provide some significant implications for other studies 
utilizing self-reported data collected via self-administered questionnaire.   
105 
 
Table 15: Repeatability Analysis for Complications and Risk Factors – DERI Repeated Surveys Sample 
Complication/Risk Factor # Cases  
# Confirmed 
Cases from 
Repeated 
Survey 
# New 
Cases in 
Repeated 
Survey 
Kappa 
Statistic P-value 
Coronary Heart Disease 8 6 0 .82 <.01 
Stroke 1 0 1 .03 .85 
Peripheral Vascular Disease 2 1 1 .46 .01 
Retinopathy 15 13 1 .80 <.01 
Neuropathy 11 11 1 .91 <.01 
Nephropathy 14 12 0 .87 <.01 
Hypertension 10 10 1 .93 <.01 
High Cholesterol 17 16 2 .80 <.01 
High Triglycerides 3 3 0 .84 <.01 
Current Smoke 3 3 0 1.00 <.01 
Ever Smoke 8 8 0 1.00 <.01 
Cataract 10 10 2 .86 <.01 
Glaucoma 2 2 1 .78 <.01 
 
Table 16: Validity Analysis for Complications and Risk Factors – DERI and EDC C10 Medical Examination 
Complication/Risk Factor 
# Cases 
(Exam) 
# Cases 
Confirmed 
by DERI 
# Unconfirmed 
Cases by DERI 
Kappa 
Statistic P-value 
Peripheral Vascular Disease 1 0 1 --- --- 
Proliferative Retinopathy 10 9 1 .92 <.01 
Neuropathy 10 6 4 .67 <.01 
Any Proteinuria 7 5 2 .62 .01 
Overt Nephropathy 2 1 1 .46 .01 
Hypertension 6 5 0 .91 <.01 
High Cholesterol 15 11 4 .73 <.01 
High Triglycerides 5 2 3 .53 .01 
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Table 17: Characteristics of Participants by Reporting Behavior and Complications/Risk Factor Status – 
DERI Repeated Survey Sample 
†Student T-test of Independent Samples | Pearson χ2 for Concordant Cases  w/ Complications/Risk Factors vs. Discordant Cases 
‡ Student T-test of Independent Samples | Pearson χ2 for All Concordant Cases vs. Discordant Cases 
 
  
 
 
 
Concordant Cases   
 
Discordant 
Cases 
(n=15) 
 
 
 
p-value† 
 
 
 
p-value‡ 
No 
Complications/ 
Risk Factors 
(n=4) 
Complications/ 
Risk Factors 
(n=11) 
Age (years) 36.0  45.9 47.3 .58 .20 
      
% Female 75.0 40 45.5 .23 .70 
% Disabled (n) 0  26.7 0  .11 .10 
% Employed 75.0 80.0 81.8 .45 .40 
% Check Glucose <3 
times/day 
25.0 20.0 45.5 .17 .16 
% Not seen physician 
in last year for routine 
care of diabetes 
0 6.7 18.2 .36 .26 
Average # of Routine 
Care Visits 
2.0 3.4 2.9 .10 .18 
% Consulted with 
Diabetes Educator in 
Past Year 
25 20 27.3 .68 .85 
% Uninsured 0 0 0 -- -- 
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Table 18: Characteristics of Participants by Reporting Behavior and Complications/Risk Factor Status – 
EDC/DERI Validity Sample 
 Concordant Cases   
 
 
Discordant 
Cases 
(n=14) 
 
 
 
 
p-value† 
 
 
 
 
p-value‡ 
No 
Complications/ 
Risk Factors 
(n=7) 
 
Complications/ 
Risk Factors 
(n=9) 
Age (years) 41.6 42.6 41.5 .85 .96 
Diabetes Duration 
(years) 
31.9 32.5 32.2 .62 .78 
HbA1C 7.4 7.1 7.1 .93 .81 
% Female 71.4 44.4 28.6 .43 .13 
% Disabled  14.3 22.2 7.1 .44 .38 
% Employed 77.8 71.4 71.4 .99 .88 
% Check Glucose <3 
times/day 
0 11.1 28.6 .22 .10 
% Not seen physician in 
last year for routine care 
of diabetes 
100 100 71.4 .07 .02 
% Consulted with 
Diabetes Educator in 
Past Year 
28.6 11.1 14.3 .87 .67 
% Uninsured 0 0 7.1 .41 .03 
†Student T-test of Independent Samples | Pearson χ2 for Concordant Cases w/ Complications/Risk Factors vs. Discordant Cases 
‡ Student T-test of Independent Samples | Pearson χ2 for All Concordant Cases vs. Discordant Cases 
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